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“ Science, my boy, is made up of mistakes, but they are mistakes which 
it is useful to make, because they lead little by little to the truth” 
-  Jules Verne, Journey to the Center of the Earth, 1864
Chapter 1 
General introduction
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G
eneral introduction
In ancient Greek mythology, it was believed that Apollo was the god of sun and light, 
but could also bring sickness as well as cure.1 Nowadays, scientists know that sunlight is 
necessary to life and evolution, but on the contrary, its  ultraviolet radiation (UV) radiation 
causes direct damage to our genetic material. When atmospheric scientists focused their 
attention on the destruction of the ozone layer in the early 1970s, a rise in skin cancer 
was predicted.2 Indeed, over the past decades, a tremendous increase in the amount of 
skin cancer and premalignant diseases has been observed.3 This was not only due to the 
destruction of the ozone layer, but also because of an increase in sun exposure. A natural 
tan became a fashion item in western countries from the 1920s onward.4,5 Despite the 
effort of governments and dermatologists in trying to change sun exposure through public 
education and media campaigns, sun exposure and a tan is still considered a “healthy” 
look in western countries. 
Skin cancer can be divided into two subcategories: malignant melanoma and non-mela-
noma skin cancer (NMSC). Malignant melanoma is known as the most aggressive type of 
skin cancer with high mortality rates.6 The group of NMSC encompasses many different 
skin malignancies, such as adnexal tumors, Merkel cell carcinomas and lymphomas, but 
is basically used to address the two most frequent skin malignancies: basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC). Recent literature has suggested the term kera-
tinocyte cancer (KC) as the preferred term for these two common skin malignancies.7,8
Accompanied with the rise in skin cancer, an increase in premalignant skin diseases has 
been observed. Bowen’s disease and actinic keratosis (AK) are known to be possible pre-
cursor lesions of SCC.9 
This thesis discusses non-invasive treatments for the two most frequent intra-epidermal 
neoplasms in Caucasians: actinic keratosis (AK) and basal cell carcinoma (BCC). In this 
chapter, both neoplasms are introduced separately.
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Actinic keratosis
Actinic keratosis (AK) is the most common premalignant skin disorder in Caucasians, 
caused by chronic UV radiation exposure. Several studies suggest that, if left untreated, 
AK might be capable of developing into squamous cell carcinoma (SCC). Percentages 
range between <1% and 16% per year.9-14 The true number remains questionable, due to 
methodological heterogeneity. It is known that there is a high recurrence rate following 
treatment, often resulting in repetitive treatments.15 Because of its frequent occurrence, 
the uncertain risk of progression into invasive SCC and the high recurrence rate, this skin 
disorder encompasses a substantial part of dermatological care and poses a burden on 
healthcare in general.11,12,16 
Epidemiology
Cumulative sun exposure is the main risk factor for the development of AK. Its prevalence 
is highest among fair-skinned patients living at low latitudes.17 As AK is not registered in 
skin cancer databases, we must depend on cohort studies to learn more about the prev-
alence and incidence. 
Data on prevalence are mainly known for Australia and the USA. Prevalence varies from 
60% in Australia to 11-26% in the USA.12,18,19 European prevalence rates are lower, with 
numbers varying between 1.4-34.1%.20-22 The reported differences are probably due to 
geographical differences and the variance in UV exposure this entails. A Dutch popula-
tion-based cohort study with a mean age of 72 years described a prevalence of 49% in 
men and 28% in women.23 Flohil et al. showed that male sex, age above 70, baldness/
hair loss and light skin phototype are risk factors.23 High sun exposure is also related to 
an increased risk of developing AK. It is therefore, that areas with higher sun exposure 
such as the face, scalp, and the dorsum of the hands and arms are affected the most. 
A personal history of SCC also predisposes patients to a risk of AK.24 Furthermore, an 
immunosuppressed status, as seen in organ transplant recipients, is an important risk 
factor for developing AK.25,26
Pathogenesis
AK usually develops because of chronic exposure to UV radiation. UV-induced damage 
to the tumor suppressor gene TP53 is associated with the induction of cancer. AKs are 
strongly associated with changes in TP53. The literature reports that up to 50% of AK and 
up to 90% of SCC have TP53 mutations.3,27-30 Most of the UV radiation that reaches the 
earth is UV-A. This type of UV penetrates the skin deeper, causing the formation of reactive 
oxygen species (ROS), thereby leading to oxidative damage to nucleic acids, membrane 
lipids and proteins.31 There is increasing evidence that oxidative stress is implicated in 
13
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photocarcinogenesis. Excessive UV exposure also initiates activation of the Ras pathway. 
Ras genes are among the most frequently mutated genes in human cancers.32 
Clinical presentation
Actinic keratosis (AK) generally presents as keratotic plaques and/or papules, often on an 
erythematous base, in sun-exposed skin such as the face, balding scalp and dorsum of 
the hands (Figure 1).33 Histologically atypical keratinocytes along the basal layer of the epi-
dermis are found with large hyperchromatic nuclei, mitotic figures, inflammatory infiltrate 
and/or hyperkeratosis.34 When examining a patient, it is important to realize that AKs can 
be more easily felt than seen.35 Some are erythematous, others are pigmented. They can 
occur solitarily, but most frequently they present as multiple lesions in a large area.36,37 
This so-called field cancerization or field change consists both of clinically obvious AKs but 
also multiple subclinical (non-visible or non-palpable) AK lesions. 
AKs are usually asymptomatic, but tenderness and itch can be reported, especially when 
lesions are thicker and multiple.38 It is also not possible to predict which AK will develop 
into SCC and which will not. Prior research has shown that certain clinical features such 
as bleeding, size > 1 cm diameter, inflammation, induration, rapid growth, erythema and 
ulceration (IDRBEU or BEIRUD criteria) might predict a higher risk of SCC development 
in AK.39 Whenever these features are present, a biopsy is often needed to differenti-
ate between AK and invasive SCC. Interestingly, spontaneous regression of AK is also 
described. 
Figure 1. Clinical presentation of actinic keratosis. 
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Treatment
The decision to treat AK can be made for several reasons: because the AK itself causes itch-
ing or is cosmetically disturbing, or to prevent development into SCC. The latter remains 
under debate. As the exact risk of progression of an AK into invasive SCC is not known, 
current guidelines advise to treat AKs. However, the risk of recurrence remains high. 
The choice of a specific treatment depends on the extensiveness and severity of the AK. 
In case of several solitary lesions, lesion-directed therapy with cryotherapy, for example, 
is sufficient.40 In the case of field change, field-directed treatment should be considered, 
as this additionally treats subclinical lesions in chronically sun exposed skin.41 In the Neth-
erlands, photodynamic therapy (PDT), 5-fluorouracil and imiquimod creams are among 
the most frequently used field-directed therapies. However, current guidelines lack clear 
treatment recommendations for clinical practice.36,42-45 Gupta et al. conducted a network 
meta-analysis in which they compared the efficacy of eight different interventions and 
concluded that 5% 5-FU is the most effective treatment for AK.46 However, randomized 
clinical studies are lacking, making it difficult to pose a more definite conclusion about the 
best and most cost-effective treatment.47 Field-directed therapies for AK are discussed 
in a separate paragraph below as the majority of treatments are used for both AK and 
superficial basal cell carcinoma (sBCC). 
Basal cell carcinoma
BCC is the most common skin cancer; it accounts for up to 80% of all NMSC.48 BCC are 
indolent tumors that metastasize very rarely.49,50 They can be locally invasive and, if ignored, 
can lead to substantial tissue destruction.51 
Epidemiology
Because of large variability in registries between countries, the exact incidence of KC in 
general and BCC specifically is difficult.3,52 In the Netherlands, BCC is registered in only one 
geographical region and only the first BCC is registered. A study performed in the Neth-
erlands showed an estimated annual percentage of increase in BCC incidence between 
2002 and 2009 of 6.8% for men and 7.9% for women. The same study showed that the 
European age-standardized (ESR) incidence rates quadrupled from 40 to 165 per 100,000 
person-years for men and from 34 to 157 for women.53 It is estimated that 30-50% of 
patients will develop at least one or more further BCC within 5 years after a primary 
tumor.3 The life-time risk of developing a BCC for the Dutch population is estimated 1:5-6.54
BCC is considered a disease of the elderly population.53,55 It is estimated that 80% of cases 
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occur in patients older than 60 years.56 However, an increase in younger patients has been 
observed.57 Men are more affected than women, except for the population younger than 
40 years. In this age category, women develop more BCC than men.58-61 
When studying the incidence rates of BCC by subtype, nodular BCC (nBCC) is the most 
common subtype, followed by superficial BCC (sBCC) and infiltrative subtypes. Interestingly, 
over the past decades, a large increase was observed for sBCC.62 A Dutch registry-based 
study showed an increase in the proportion of sBCC from 17% in 1991 to 30% in 2007.63 
The rising incidence can be explained by several factors: increased UV light exposure, 
depletion of the ozone layer in several geographical regions and an increased awareness 
that leads to more visits to healthcare professionals and therefore an increase in diagno-
sis. Besides UV, other factors such as the use of immunosuppressive or photosensitizing 
medication influence the susceptibility to develop KC.64,65 Additionally, there is a genetic 
susceptibility that contributes to the development of BCC, as is known in basal cell nevus 
syndrome (BCNS) for example.66 
Pathogenesis
Until the late 1990s, the molecular biology of BCC was a “black box”, but in the past 
decade, our understanding of its molecular pathogenesis has increased.67 BCC belongs 
to the group of cancers in which deregulated Hedgehog (HH) signaling is of crucial impor-
tance.67,68 BCNS patients appear to carry heritable mutations in the patched-1 (PTCH1) 
gene, a tumor suppressor gene that acts as an inhibitor of the HH pathway. It is now known 
that approximately 90% of sporadic BCC also have identifiable mutations in at least one 
allele of the PTCH1 gene.67 In short, PTCH1 encodes for a transmembrane protein that 
can bind to the sonic hedgehog (SHH) protein. In normal conditions, the HH protein sup-
presses activation of the transmembrane protein smoothened (SMO). This suppression 
prevents SMO targeting of Gli transcription factors and activation of intra-nuclear target 
genes is hindered. In the case of activating mutations in SMO or loss of function mutations 
in PTCH1, no inhibition of downstream Gli transcription can take place, resulting in tumor 
proliferation. Figure 2 schematically demonstrates HH signaling. Approximately 10% of 
BCC are caused by activating mutations in SMO.67
Under physiological conditions, SHH is responsible for the proliferative expansion of the 
follicle epithelium required for maturation of the follicle. It is suggested that BCC arise 
from cells of the upper infundibulum and inter-follicular epidermis.69,70 The development 
of these epidermal cells and hair bud formation is regulated by canonical Wingless (WNT) 
signaling.69 There are suggestions that deregulation of the Wnt pathway causes intra-nu-
clear accumulation of β-catenin, leading to further proliferation of HH pathway-driven 
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neoplasia, such as BCC.71 
Figure 2. Schematic representation of hedgehog (HH) signaling. 
The hedgehog inhibitor pathway. (A) In the absence of the sonic hedgehog ligand, the patched receptor (PTCH) 
inhibits the activity of smoothened (Smo), allowing suppressor of fused (SUFU) to bind and to inactivate Gli tran-
scription factors. (B) Binding of the sonic hedgehog ligand to PTCH allows the activation of Smo, inhibiting the 
binding of SUFU to Gli. The Gli transcription factors are then able to enter the nucleus and modulate transcription 
of Hedgehog pathway-associated genes. Reprinted with permission of the Nature publishing group: Lear JT et al; 
Br. J. Cancer, 2014; 111(8):1476-81. Doi: 10.1038/bjc.2014.270.72
Clinical presentation and diagnosis     
BCC mostly present as a translucent or pearly colored papules or plaques with telangiecta-
sia. The clinical appearance depends on the histological subtype. Diagnosis can usually be 
made on its clinical appearance: approximately 72-80% of tumors are correctly diagnosed 
by clinical examination.73-76 Around 8% of all BCC occur on sun-exposed areas such as the 
head and neck area.77 BCC can be roughly divided in four categories: superficial, nodular, 
micronodular and infiltrative. These can be categorized in non-aggressive (superficial and 
nodular) and aggressive (infiltrative and micronodular) BCC. Figure 3 shows the clinical 
presentation of superficial, nodular and infiltrative subtypes. 
Superficial BCC present as an eczema-like plaque frequently located on the trunk. Some-
times it is accompanied by slight keratosis. Histologically atypical basaloid cells are seen 
that stay connected to the epidermal surface or hair follicle. A tumor cell palisade at the 
periphery of tumor nests and artificial retraction from surrounding stroma can be seen.78,79 
Nodular BCC is the most frequent subtype (approximately 60%) and generally presents as 
a round raised papule or nodule with well-defined edges, which has a translucent or pearly 
appearance with telangiectasia or sometimes pigmentation.80 Histologically, this variant 
is characterized by nests of atypical basaloid cells in the papillary or reticular dermis, fre-
quently accompanied by an artificial retraction from the surrounding stroma.78,79 Tumor 
nests frequently show peripheral cell palisading. 
Infiltrative (aggressive) and micronodular BCC present as shiny pale or white patches 
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or plaques with poorly defined borders and might have an atrophic appearance with 
induration. Histologically, this subtype typically spreads further than can be observed clin-
ically.81 Basaloid cells invading the deeper dermis are observed histologically. In infiltrative 
tumors, peripheral palisading and stromal retraction are fairly rare.79 Some BCC can con-
tain melanin pigmentation within basaloid cells and macrophages, causing a pigmented 
appearance. This may occur in all subtypes.
It is important to distinguish the different subtypes of BCC, as a different therapeutic 
approach is necessary to prevent recurrence of tumors. The use of dermatoscopy and 
taking a biopsy specimen for histopathological examination increase the diagnostic 
accuracy for the BCC subtype.82,83 It is advised to take a punch biopsy to determine the 
histological subtype, but clinicians should be aware that a substantial part of BCC consist 
of more than one subtype, so called mixed-type BCCs.84-86 A punch biopsy might detect 
only one histological subtype of BCC, leading to a possible under-treatment in cases where 
the most aggressive part is not identified in the biopsy. 
Figure 3. Clinical presentation of superficial (a), nodular (b) and infiltrative (c) BCC subtypes 
A B C
Treatment
Treatment of BCC can be divided into invasive and non-invasive therapies. Up to now, 
surgery has been considered the gold standard treatment for all BCC subtypes because of 
the associated high cure rates and histological confirmation.87-89 Because of its superficial 
growth, sBCC are especially accessible to non-invasive therapy such as topically applied 
treatments and photodynamic therapy. 
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Topical treatment of actinic keratosis 
and superficial basal cell carcinoma
In this paragraph, non-invasive topical treatments for sBCC and field-directed treatments 
for AK are discussed together. 
5-fluorouracil
5% 5-Fluorouracil (5-FU) cream was introduced and approved by the US Food and Drug 
association (FDA) in 1957 as a new anti-tumor treatment.90,91 Its approval was based on the 
first study in which a 93% success rate was described for sBCC. Other studies confirmed 
its efficacy and tolerability.91,92 For AK, several studies describe a complete clearance rate 
varying from 43-96% with a recurrence percentage of 43-44% after 12-36 months.47,93,94
The mechanism of action mainly depends on its cytotoxic effect. After entering the cell, 
enzymatic reactions lead to conversion in three important metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine tri-
phosphate (FUTP). These metabolites interfere with DNA and RNA through the inhibition of 
thymidylate synthetase (TS), which is required for DNA synthesis and repair. Eventually 5-FU 
influences DNA repair mechanisms, ultimately leading to cell death.95 In dermato-oncology, 
5% 5-FU (Efudix®) is mainly used for intra-epithelial (pre)malignant skin diseases such as AK, 
Bowens disease and sBCC. It is not indicated to treat high-risk BCC or nodular BCC because 
of low cure rates.96 Possible side effects are pain, a burning sensation, erythema, crusting, 
erosions and edema. Side effects generally occur on the treated and diseased skin. This is 
supported by research showing that healthy skin cells are fairly resistant to the described 
cytotoxic effects of 5-FU compared to rapidly proliferating tumor cells.91,97 5-FU cream is pro-
duced in two different dosages: 0.5% and 5%. The latter is the only available concentration 
in the Netherlands (Efudix®, Meda Pharma). For both sBCC and AK, the 5% 5-FU ointment 
is applied twice daily for 3-4 weeks until erosions and crusts develop. 
Imiquimod
Imiquimod is another topical cream registered to treat (pre)malignant skin disorders. In 
the Netherlands, it is used to treat actinic keratosis and sBCC.98 It was first approved to 
treat small primary sBCC in 2004 by the U.S. FDA. Studies have reported success rates 
of 87-88% for sBCC.99,100 A more recent study revealed that 5% Imiquimod cream was 
inferior to surgery for sBCC, but showed acceptable cure rates of 83.6% and 82.5% at 3 
and 5 years follow-up.101,102 For AK, complete clearance rates vary between 24% and 73% 
after 5% imiquimod.93,103 In general, studies that assessed efficacy are very heterogenous; 
follow-up periods vary and there are only a few randomized comparative studies. More 
recently, imiquimod 3.75% (Zyclara ®) was developed. A complete clearance rate of 34% 
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and a median reduction from baseline in number of AK of 80% were described in a pla-
cebo controlled study.104
Imiquimod is a synthetic nucleoside analogue of the imidazoquinoline family.105 It acts 
as an immunomodulator with antitumoral and antiviral efficacy. Its activity is initiated by 
toll-like receptor (TLR) 7 and 8 signaling cascades, leading to the release of inflammatory 
cytokines and other mediators. The release of natural killer cells is also stimulated and 
Th1 cytokines are produced. Subsequently, tumor-directed cellular immune responses are 
activated.106 It is also reported to induce apoptosis. Furthermore, a recent study by Wolff 
et al. demonstrated a tumor-specific mechanism of action by repressing HH signaling by 
negatively modulating Gli activity in BCC.105 For sBCC, the treatment regimen consists of 
once daily application, five days a week, for a period of 6 consecutive weeks. To treat AK, 
the ointment should be applied once daily, 3 days a week (e.g. Monday-Wednesday-Friday) 
for 4 weeks. Evaluation after four weeks is indicated and, in case of an insufficient effect, 
this should be repeated for an additional period of 4 weeks. The new formulation imiqui-
mod 3.75%, registered for field AK, has a different dosing regimen: it should be applied 
once daily for two weeks. After an interval of two weeks without treatment, the same 
regimen is repeated. The side effects of imiquimod are comparable to those of 5-FU: pain, 
a burning sensation, erythema, erosions and edema. Because of its immune-modulatory 
effect, patients can report flu-like symptoms during treatment as well. 
Photodynamic therapy
Photodynamic therapy (PDT), also called photochemotherapy, combines a light source 
with a photosensitizer. In dermato-oncology, PDT is primarily used to treat AK, sBCC and 
Bowens disease. To obtain an optimal photodynamic reaction, three components are 
needed: 1) a photosensitizer; 2) light that can be absorbed by the photosensitizer and 3) 
oxygen. When these components act together with the surrounding tissue, a photody-
namic reaction occurs. Commonly available topical photosensitizers are 5-aminolevulinic 
acid (5-ALA) and its methyl ester methyl-aminolevulinate (MAL). Both photosensitizers 
are precursor drugs of the photosensitizer protoporphyrin IX (PpIX). PpIX accumulates in 
epidermal, metabolically active cells. When illuminated by a light source with the appropri-
ate wavelength, the release of reactive oxygen radicals is observed.107 Subsequently, this 
causes cellular (mitochondrial) damage, apoptosis and necrosis in tumor cells (Figure 4). 
Because there is a higher conversion of PpIX in metabolically active cells, such as tumor 
cells, PDT is a tumor-specific treatment in which damage to healthy tissue is minimal. PDT is 
an in-hospital treatment, mostly performed by trained nurses. MAL is the most commonly 
used photosensitizer in the European Union for both BCC and AK treatment. On the other 
hand, 5-ALA is registered in the US for both BCC and AK, but in Europe for AK only.41,108,109 
For sBCC, the MAL treatment scheme used in most Dutch hospitals involves two ses-
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sions, separated by one week. During each session, MAL (Metvix®, Galderma) ointment 
is applied to the tumor surface with a margin of 5 mm in the surrounding tissue. After a 
3-hour dark interval, the skin is illuminated with a light emitting diode (LED) light source for 
7 minutes with a fluence of 37 J/cm2. Clearance rates between 72 and 84% are described 
after MAL-PDT.108,110,111
De Haas et al. developed a fractionated two-fold illumination schedule (two illuminations 
on one day) using 5-ALA cream to treat sBCC. This treatment regimen is used in sev-
eral Dutch hospitals for sBCC, along with the more frequent used conventional MAL-PDT 
treatment. 5-ALA cream is applied in the same manner as MAL-PDT, and after 4 hours of 
waiting the tumor is illuminated with a fluence of 20 J/cm2 for 4 minutes. Subsequently, the 
tumor area is covered and after 2 hours is illuminated again with 80 J/cm2 for 18 minutes. 
Clearance rates described were 97% one year post-treatment, which is higher than for 
conventional MAL-PDT.112 
Conventional MAL-PDT treatment using MAL cream (Metvix®, Galderma) for AK includes 
one illumination session. After a 3-hour dark interval, the skin is illuminated once with a 
red light emitting diode (LED) light source (~630 nm +/- 5 nm) for 7 minutes and a fluence 
of 37 J/cm2. Placebo controlled studies report complete clearance rates in 69-91% of AK 
lesions 3 months post-treatment after one or two sessions with MAL-PDT.113-116 When 
evaluating the efficacy of two versus one illumination session in MAL-PDT, Tarstedt et 
al. concluded that a single illumination is almost equally effective as two illuminations.116 
Recently, daylight PDT has been introduced. The initial trials from Scandinavia reported 
clearance rates varying from 75-79%.118 117,119 Advantages are convenience for the patient 
and tolerability with less pain sensation compared to conventional PDT.120 An important 
limitation can be the weather conditions. 
Most reported side effects during conventional PDT are pain or a burning sensation during 
illumination and post-treatment erythema, crusting and scaling. Sometimes, erosions can 
appear. Serious pain during illumination can be a drawback for patients, especially in AK 
patients.121 Because of this, illumination schedules and light sources are being studied 
and optimized.
Ingenol mebutate
Ingenol mebutate is a relatively new topical treatment, approved for the treatment of AK 
by the FDA in 2012. It has been available in the Netherlands since 2013. The active sub-
stance is derived from the plant Euphorbia peplus. Its mechanism of action is still not fully 
understood, but it is hypothesized that it has a dual mechanism: immediate cytotoxicity 
with the occurrence of mitochondrial edema and an immunomodulatory effect through 
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the production of pro-inflammatory cytokines and the recruitment of neutrophils. 24 The 
first placebo-controlled clinical trial on ingenol mebutate showed a complete AK clear-
ance rate of 42.2% in the head and neck area, compared to 3.7% in the placebo group, 8 
weeks post-treatment. The median reduction in the number of AK was 83%. At long-term 
follow-up (12 months), the lesion reduction from baseline was 87.2% in the head and neck 
area and 86% for the trunk and extremities. 
Figure 4. The mechanisms of action of photodynamic therapy in tumors. 
The photosensitizer (PS) absorbs light and an electron moves to the first short-lived excited singlet state. This 
is followed by intersystem crossing, in which the excited electron changes its spin and produces a longer-lived 
triplet state. The PS triplet transfers energy to ground-state triplet oxygen, which produces reactive singlet oxygen 
(1O2). 
1O2 can directly kill tumor cells by the induction of necrosis and/or apoptosis, can cause destruction of 
the tumor vasculature and produces an acute inflammatory response that attracts leukocytes such as dendritic 
cells and neutrophils.
Reprinted by permission from Macmillan Publishers Ltd: Nat. Rev. Cancer122, copyright (2006). 
Ingenol mebutate (Picato®, Leopharma) is available in two concentrations: 1) 150 µg/g, 
used for the face and scalp, applied once daily on three consecutive days and 2) 500 
µg/g, used for trunk and extremities applied once daily on two consecutive days. The fact 
that treatment only lasts two to three days is a major advantage for patients, especially 
when compared to other topical ointments such as imiquimod or 5-FU. The side effects 
of ingenol mebutate are also comparable to those of 5-FU and imiquimod. Because of the 
short duration of treatment, this influences compliance in a positive way. There have been 
a few small studies reporting on the use of ingenol mebutate to treat sBCC; however, the 
studies were small and the evidence is limited.123-125 sBCC is not yet an approved indication 
for ingenol mebutate treatment.
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Aims and outline of this thesis 
Nowadays, treatment of KC is not only a matter of offering the most effective treatment to 
a patient. Cosmetic outcome, the cost of treatment and patient preference are increasingly 
important, especially because of the growing incidence of (pre)malignant skin disorders 
in the younger population.53,58 This stresses the need to determine the optimal therapy 
and to search for new non-invasive treatments. 
For AK, few head-to-head trials are available, leading to a lack of evidence-based treatment 
recommendations for daily practice. The AK studies in this thesis concentrated on an alter-
native illumination source for PDT and a large multi-center randomized trial comparing 
the four most frequently applied therapies. 
Treatment of sBCC with self-applicable creams is associated with local adverse effects 
and good compliance is inevitable to achieve good therapeutic results. Photodynamic 
therapy results in fewer side effects, but recent studies have shown that it is less effective 
compared to self-applied creams such as imiquimod or 5-fluorouracil.110,126 In patients 
where compliance is doubtful, an in-hospital non-invasive treatment such as PDT could 
be desirable. However, the efficacy of PDT must increase. Therefore, the search for opti-
mal light sources and illumination schemes continues. The studies on sBCC performed 
in this thesis focused on the optimization of PDT protocols and evaluated the efficacy of 
a possible new topical treatment.
This thesis aimed to answer the following questions regarding the effectiveness of:
- PDT using pulsed-dye laser illumination for AK (chapter 2.2)
- the four most frequently used field-directed therapies for AK (chapter 2.3)
- topical sinecatechin 10% ointment for sBCC (chapter 3)
- two-fold ALA-PDT compared to conventional MAL-PDT for sBCC (chapter 4.1 and 
chapter 4.2)
- ambulatory PDT for sBCC (chapter 4.3)
Outline of the thesis
In chapter 2, we discuss the available literature regarding the different treatment modal-
ities for AK. The efficacy of laser illumination as an alternative PDT light source for AK is 
assessed. This chapter also contains the results of a large randomized controlled effec-
tiveness trial comparing four common topical treatments for AK. 
Chapter 3 describes a randomized study evaluating the efficacy of topical green tea oint-
ment for sBCC. 
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Chapter 4 is devoted to photodynamic therapy for sBCC. Different illumination schedules 
and illumination sources are discussed, including the results of a randomized controlled 
trial comparing two different PDT protocols. 
Chapter 5 provides a discussion of the results and the implications for clinical practice. 
24
References
1. Mead MN. Benefits of sunlight: a bright spot for human health. Environmental health perspectives. 
2008;116(4):A160-167.
2. Johnston H. Reduction of stratospheric ozone by nitrogen oxide catalysts from supersonic trans-
port exhaust. Science (New York, NY). 1971;173(3996):517-522.
3. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375(9715):673-685.
4. Wilkinson S. A short history of tanning. the guardian. 2012.
5. Fitzpatrick L. From Elizabeth Bennet to Barbie: sun tanning through the ages. JAMA dermatology. 
2014;150(4):406.
6. Mayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education, and trends for mel-
anoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, 
clinical strategies, and diagnostic technology. Journal of the American Academy of Dermatology. 
2014;71(4):599.e591-599.e512; quiz 610, 599.e512.
7. Sanchez G, Nova J, Rodriguez-Hernandez AE, et al. Sun protection for preventing basal cell and 
squamous cell skin cancers. The Cochrane database of systematic reviews. 2016;7:Cd011161.
8. Albert MR, Weinstock MA. Keratinocyte carcinoma. CA: a cancer journal for clinicians. 
2003;53(5):292-302.
9. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. The British journal 
of dermatology. 2006;155(1):9-22.
10. Dinehart SM, Nelson-Adesokan P, Cockerell C, Russell S, Brown R. Metastatic cutaneous squa-
mous cell carcinoma derived from actinic keratosis. Cancer. 1997;79(5):920-923.
11. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell 
carcinoma. Lancet (London, England). 1988;1(8589):795-797.
12. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. Journal of the Amer-
ican Academy of Dermatology. 2000;42(1 Pt 2):4-7.
13. Gloster HM, Jr., Brodland DG. The epidemiology of skin cancer. Dermatologic surgery : official 
publication for American Society for Dermatologic Surgery [et al]. 1996;22(3):217-226.
14. Callen JP, Bickers DR, Moy RL. Actinic keratoses. Journal of the American Academy of Dermatology. 
1997;36(4):650-653.
15. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. European journal of 
dermatology : EJD. 2006;16(6):599-606.
16. Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presen-
tation and treatment. The Australasian journal of dermatology. 2007;48(2):67-74; quiz 75-66.
17. Green AC. Epidemiology of actinic keratoses. Current problems in dermatology. 2015;46:1-7.
18. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a 
queensland community. The Journal of investigative dermatology. 2000;115(2):273-277.
19. Eder J, Prillinger K, Korn A, Geroldinger A, Trautinger F. Prevalence of actinic keratosis among 
dermatology outpatients in Austria. The British journal of dermatology. 2014;171(6):1415-1421.
20. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar 
keratoses II analytical results of the South Wales Skin Cancer Study. British journal of cancer. 
1996;74(8):1308-1312.
21. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C. Prevalence of actinic 
keratoses and associated factors in a representative sample of the Italian adult population: 
Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Archives of dermatol-
ogy. 2006;142(6):722-726.
22. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic 
keratosis in a Merseyside population. The British journal of dermatology. 2000;142(6):1154-1159.
23. Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic 
keratosis and its risk factors in the general population: the Rotterdam Study. The Journal of 
investigative dermatology. 2013;133(8):1971-1978.
24. Dreno B, Amici JM, Basset-Seguin N, Cribier B, Claudel JP, Richard MA. Management of actinic 
keratosis: a practical report and treatment algorithm from AKTeam expert clinicians. Journal of 
the European Academy of Dermatology and Venereology : JEADV. 2014;28(9):1141-1149.
25
G
eneral introduction
25. Iannacone MR, Sinnya S, Pandeya N, et al. Prevalence of Skin Cancer and Related Skin Tumors 
in High-Risk Kidney and Liver Transplant Recipients in Queensland, Australia. The Journal of 
investigative dermatology. 2016;136(7):1382-1386.
26. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant 
and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. 
Journal of the American Academy of Dermatology. 1995;33(2 Pt 1):222-229.
27. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human 
skin cancer: p53, apoptosis, and tumor promotion. The journal of investigative dermatology 
Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for 
Dermatological Research. 1996;1(2):136-142.
28. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 
1994;372(6508):773-776.
29. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic 
keratosis lesions and squamous cell cancers. Cancer letters. 1994;85(1):23-29.
30. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte 
proliferation. Journal of the American Academy of Dermatology. 2013;68(1 Suppl 1):S10-19.
31. Timares L, Katiyar SK, Elmets CA. DNA damage, apoptosis and langerhans cells--Activators of 
UV-induced immune tolerance. Photochemistry and photobiology. 2008;84(2):422-436.
32. Khavari PA. Modelling cancer in human skin tissue. Nature reviews Cancer. 2006;6(4):270-280.
33. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. Journal of the 
American Academy of Dermatology. 2000;42(1 Pt 2):8-10.
34. Rossi R, Mori M, Lotti T. Actinic keratosis. International journal of dermatology. 2007;46(9):895-904.
35. Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. The 
British journal of dermatology. 2016.
36. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment 
algorithm for actinic keratoses: a European Consensus. European journal of dermatology : EJD. 
2008;18(6):651-659.
37. Lanoue J, Chen C, Goldenberg G. Actinic keratosis as a marker of field cancerization in excision 
specimens of cutaneous malignancies. Cutis. 2016;97(6):415-420.
38. Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. 
Journal of the American Academy of Dermatology. 2013;68(1 Suppl 1):S2-9.
39. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good 
from the bad ones? European journal of dermatology : EJD. 2006;16(4):335-339.
40. Goldberg LH, Kaplan B, Vergilis-Kalner I, Landau J. Liquid nitrogen: temperature control in the 
treatment of actinic keratosis. Dermatologic surgery : official publication for American Society for 
Dermatologic Surgery [et al]. 2010;36(12):1956-1961.
41. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. The 
British journal of dermatology. 2008;159(6):1245-1266.
42. NVDV. Richtlijn actinische keratose. 2012.
43. de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Der-
matologists’ guidelines for the care of patients with actinic keratosis 2017. The British journal of 
dermatology. 2017;176(1):20-43.
44. Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) Guidelines for 
the Treatment of Actinic Keratosis - International League of Dermatological Societies in coop-
eration with the European Dermatology Forum - Short version. Journal of the European Academy 
of Dermatology and Venereology : JEADV. 2015;29(11):2069-2079.
45. Beljaards RC, van der Sande A. . Update richtlijn actinische keratosen 2017. Nederlands Tijdschrift 
voor Dermatologie en Venereologie. 2017;27 190-192.
46. Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in 
nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on 
a Cochrane review. The British journal of dermatology. 2013;169(2):250-259.
47. Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. The Cochrane 
database of systematic reviews. 2012;12:CD004415.
48. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. The New England journal of medicine. 
2005;353(21):2262-2269.
26
49. Nguyen-Nielsen M, Wang L, Pedersen L, et al. The incidence of metastatic basal cell carcinoma 
(mBCC) in Denmark, 1997-2010. European journal of dermatology : EJD. 2015;25(5):463-468.
50. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis 
dependent on anatomic site and spread of disease. European journal of cancer (Oxford, England 
: 1990). 2014;50(4):774-783.
51. Brinkhuizen T, Reinders MG, van Geel M, et al. Acquired resistance to the Hedgehog pathway 
inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell 
carcinoma. Journal of the American Academy of Dermatology. 2014;71(5):1005-1008.
52. Goodwin RG, Holme SA, Roberts DL. Variations in registration of skin cancer in the United King-
dom. Clinical and experimental dermatology. 2004;29(3):328-330.
53. Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends in Basal cell 
carcinoma incidence rates: a 37-year Dutch observational study. The Journal of investigative der-
matology. 2013;133(4):913-918.
54. Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future 
trends of primary basal cell carcinoma in the Netherlands. Acta dermato-venereologica. 
2011;91(1):24-30.
55. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell 
carcinoma. Additional evidence from a UK primary care database study. International journal of 
cancer Journal international du cancer. 2007;121(9):2105-2108.
56. Diffey BL, Langtry JA. Skin cancer incidence and the ageing population. The British journal of 
dermatology. 2005;153(3):679-680.
57. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjaer SK. Trends in the incidence of non-
melanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish 
women. International journal of cancer Journal international du cancer. 2010;127(9):2190-2198.
58. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell 
carcinomas in a population younger than 40 years. Jama. 2005;294(6):681-690.
59. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, 
location and histopathological subtype. The British journal of dermatology. 2002;147(1):41-47.
60. Cox NH. Basal cell carcinoma in young adults. The British journal of dermatology. 1992;127(1):26-
29.
61. Leffell DJ, Headington JT, Wong DS, Swanson NA. Aggressive-growth basal cell carcinoma in young 
adults. Archives of dermatology. 1991;127(11):1663-1667.
62. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site 
distribution. The British journal of dermatology. 2006;155(2):401-407.
63. Arits AH, Schlangen MH, Nelemans PJ, Kelleners-Smeets NW. Trends in the incidence of basal 
cell carcinoma by histopathological subtype. Journal of the European Academy of Dermatology and 
Venereology : JEADV. 2011;25(5):565-569.
64. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant 
recipients occur more frequently than previously recognized in a temperate climate. Transplan-
tation. 2004;77(4):574-579.
65. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study 
of skin cancer incidence and prevalence in renal transplant recipients. The British journal of 
dermatology. 2006;154(3):498-504.
66. Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Seminars in cutaneous 
medicine and surgery. 2012;31(4):204-210.
67. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nature reviews Cancer. 2008;8(10):743-
754.
68. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal 
cell nevus syndrome. Science (New York, NY). 1996;272(5268):1668-1671.
69. Yang SH, Andl T, Grachtchouk V, et al. Pathological responses to oncogenic Hedgehog signaling in 
skin are dependent on canonical Wnt/beta3-catenin signaling. Nature genetics. 2008;40(9):1130-
1135.
70. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of 
basal cell carcinoma. Nature cell biology. 2010;12(3):299-305.
71. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nature reviews Drug dis-
27
G
eneral introduction
covery. 2006;5(12):997-1014.
72. Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of 
advanced basal cell carcinoma: a UK perspective. British journal of cancer. 2014;111(8):1476-
1481.
73. Heal CF, Raasch BA, Buettner PG, Weedon D. Accuracy of clinical diagnosis of skin lesions. The 
British journal of dermatology. 2008;159(3):661-668.
74. Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS. Accuracy and 
predictors of basal cell carcinoma diagnosis. Dermatologic surgery : official publication for American 
Society for Dermatologic Surgery [et al]. 2005;31(5):534-537.
75. Schmitz L, Dirschka T. [Therapy of basal cell carcinoma]. Der Hautarzt; Zeitschrift fur Dermatologie, 
Venerologie, und verwandte Gebiete. 2016;67(6):483-499.
76. Ek EW, Giorlando F, Su SY, Dieu T. Clinical diagnosis of skin tumours: how good are we? ANZ 
journal of surgery. 2005;75(6):415-420.
77. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the his-
tological subtypes of basal cell carcinoma. A possible indicator of differing causes. Archives of 
dermatology. 1997;133(5):593-596.
78. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Modern pathol-
ogy : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006;19 Suppl 
2:S127-147.
79. Barnhill RL. Textbook of dermatopathology. McGraw-Hill Professional Publishing; 1998.
80. Miller SJ. Biology of basal cell carcinoma (Part I). Journal of the American Academy of Dermatology. 
1991;24(1):1-13.
81. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagno-
sis, histopathology, and management. The Yale journal of biology and medicine. 2015;88(2):167-179.
82. Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic 
variability of global and local features and accuracy of diagnosis. Journal of the American Academy 
of Dermatology. 2010;62(1):67-75.
83. Nelson SA, Scope A, Rishpon A, et al. Accuracy and confidence in the clinical diagnosis of basal cell 
cancer using dermoscopy and reflex confocal microscopy. International journal of dermatology. 
2016.
84. Roozeboom MH, Mosterd K, Winnepenninckx VJ, Nelemans PJ, Kelleners-Smeets NW. Agree-
ment between histological subtype on punch biopsy and surgical excision in primary basal 
cell carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV. 
2013;27(7):894-898.
85. Mosterd K, Thissen MR, van Marion AM, et al. Correlation between histologic findings on punch 
biopsy specimens and subsequent excision specimens in recurrent basal cell carcinoma. Journal 
of the American Academy of Dermatology. 2011;64(2):323-327.
86. Wolberink EA, Pasch MC, Zeiler M, van Erp PE, Gerritsen MJ. High discordance between punch 
biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. Journal 
of the European Academy of Dermatology and Venereology : JEADV. 2013;27(8):985-989.
87. NVDV. Evidence based richtlijn basaalcelcarcinoom 2015. 2015.
88. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. 
The Cochrane database of systematic reviews. 2007(1):Cd003412.
89. van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs’ micrographic surgery 
for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European 
journal of cancer (Oxford, England : 1990). 2014;50(17):3011-3020.
90. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of 
tumour-inhibitory compounds. Nature. 1957;179(4561):663-666.
91. Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological dis-
orders. The Journal of dermatological treatment. 2009;20(6):328-335.
92. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal 
cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatologic 
surgery : official publication for American Society for Dermatologic Surgery [et al]. 2007;33(4):433-
439; discussion 440.
93. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study 
28
of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients 
with actinic keratoses: a comparison of clinical and histological outcomes including 1-year fol-
low-up. The British journal of dermatology. 2007;157 Suppl 2:34-40.
94. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil 
cream and 5% fluorouracil cream applied to each side of the face in patients with actinic kera-
tosis. Clinical therapeutics. 2002;24(6):990-1000.
95. Ceilley RI. Mechanisms of action of topical 5-fluorouracil: review and implications for the treat-
ment of dermatological disorders. The Journal of dermatological treatment. 2012;23(2):83-89.
96. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell 
carcinoma. Archives of dermatology. 1978;114(7):1021-1022.
97. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. Journal of the American Academy 
of Dermatology. 1981;4(6):633-649.
98. Kelleners-Smeets NW. Evidence based richtlijn basaalcelcarcinoom 2014. 2014.
99. Bath-Hextall F, Leonardi-Bee J, Somchand N, Webster A, Delitt J, Perkins W. Interventions for 
preventing non-melanoma skin cancers in high-risk groups. The Cochrane database of systematic 
reviews. 2007(4):CD005414.
100. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after 
treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of 
randomized and nonrandomized trials. The British journal of dermatology. 2012;167(4):733-756.
101. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for 
nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised 
controlled trial. The Lancet Oncology. 2014;15(1):96-105.
102. Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery Versus 5% Imiquimod for Nodular and 
Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. The 
Journal of investigative dermatology. 2017;137(3):614-619.
103. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic ker-
atosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled 
trials. Journal of the American Academy of Dermatology. 2004;50(5):714-721.
104. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the 
treatment of actinic keratoses: results of two placebo-controlled studies of daily application to 
the face and balding scalp for two 3-week cycles. Journal of the American Academy of Dermatology. 
2010;62(4):573-581.
105. Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM. Imiquimod directly 
inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI 
phosphorylation. Oncogene. 2013;32(50):5574-5581.
106. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod 
interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. The Journal 
of investigative dermatology. 2006;126(6):1338-1347.
107. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for 
photodynamic therapy. Journal of photochemistry and photobiology B, Biology. 1992;14(4):275-
292.
108. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate 
photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 
12-month follow-up. Journal of the European Academy of Dermatology and Venereology : JEADV. 
2008;22(11):1302-1311.
109. Szeimies RM, Morton CA, Sidoroff A, Braathen LR. Photodynamic therapy for non-melanoma 
skin cancer. Acta dermato-venereologica. 2005;85(6):483-490.
110. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus 
topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, 
randomised controlled trial. The Lancet Oncology. 2013;14(7):647-654.
111. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic 
therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Euro-
pean journal of dermatology : EJD. 2008;18(5):547-553.
112. de Haas ER, Kruijt B, Sterenborg HJ, Martino Neumann HA, Robinson DJ. Fractionated illumination 
significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid 
29
G
eneral introduction
photodynamic therapy. The Journal of investigative dermatology. 2006;126(12):2679-2686.
113. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical 
methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: 
a prospective, randomized study. The Journal of dermatological treatment. 2003;14(2):99-106.
114. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-ami-
nolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. 
Journal of the American Academy of Dermatology. 2002;47(2):258-262.
115. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevuli-
nate for actinic keratosis: results of a prospective randomized multicenter trial. Journal of the 
American Academy of Dermatology. 2003;48(2):227-232.
116. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study 
to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic 
keratosis of the face and scalp. Acta dermato-venereologica. 2005;85(5):424-428.
117. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 
8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded 
randomized clinical trial. The British journal of dermatology. 2009;160(6):1308-1314.
118. Wiegell SR, Skodt V, Wulf HC. Daylight-mediated photodynamic therapy of basal cell carcinomas 
- an explorative study. Journal of the European Academy of Dermatology and Venereology : JEADV. 
2013.
119. Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX 
by daylight is as effective as and less painful than conventional photodynamic therapy for actinic 
keratoses; a randomized, controlled, single-blinded study. The British journal of dermatology. 
2008;158(4):740-746.
120. Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate 
cream is effective and nearly painless in treating actinic keratoses: a randomised, investiga-
tor-blinded, controlled, phase III study throughout Europe. Journal of the European Academy of 
Dermatology and Venereology : JEADV. 2015;29(12):2342-2348.
121. Sandberg C, Stenquist B, Rosdahl I, et al. Important factors for pain during photodynamic therapy 
for actinic keratosis. Acta dermato-venereologica. 2006;86(5):404-408.
122. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nature 
reviews Cancer. 2006;6(7):535-545.
123. Jung YS, Lee JH, Bae JM, Kim GM. Superficial Basal Cell Carcinoma Treated with Two Cycles of 
Ingenol Mebutate Gel 0.015. Annals of dermatology. 2016;28(6):796-797.
124. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) 
gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase 
IIa trial. The Australasian journal of dermatology. 2010;51(2):99-105.
125. Del Rosso JQ. Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic 
Keratosis. The Journal of clinical and aesthetic dermatology. 2016;9(11 Suppl 1):S3-s11.
126. Roozeboom MH, Arits AH, Mosterd K, et al. Three-Year Follow-Up Results of Photodynamic 
Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A 
Single-Blind, Noninferiority, Randomized Controlled Trial. The Journal of investigative dermatology. 
2016;136(8):1568-1574.

Chapter 2 
Evidence based treatment of actinic keratosis

“There is nothing wrong with dirty data as long as you have a clear mind”
- Dr. Langan, EADV fostering resident course – Clinical research & epidemiology, 2016
Chapter 2.1 
Evidence based treatment of actinic keratosis: 
review of the literature
J.P.H.M. Kessels, N.W.J. Kelleners-Smeets, K. Mosterd
Nederlands tijdschrift voor dermatologie en venereologie 2014; 24(9):558-562
34
2.1  |   Evidence based treatm
ent of actinic keratosis: review
 of the literature
35
Introduction
Skin cancer is a major public health issue, as its incidence is increasing rapidly. Actinic ker-
atosis (AK) is the most prevalent precancerous chronic skin condition, caused by chronic 
UV radiation exposure.  AK can persist, regress or transform into squamous cell carcinoma 
(SCC).1,2 It is among the most common conditions treated by dermatologists.3 Previous 
research by Flohil et al. showed a prevalence of 49% in men and 28% in women above the 
age of 45 in the Netherlands.4 The number of newly diagnosed lesions in the Netherlands 
is currently estimated at 160.000/year. It is expected that the number of patients with AK 
will rise even further in the future, also due to already experienced sun exposure during 
life.5 Furthermore, phenotypic characters of the Dutch population with light skin type have 
an increased risk for AK compared to darker skin types. 
AKs have a high recurrence rate, often resulting in frequently repeated treatments. The 
current opinion is that recurrence of AK can be a result of field cancerization; AKs arise 
in a skin area that has diffuse precancerous damage, which may not be clinically visible. 
This phenomenon has been confirmed in mice.6 Field-directed therapy offers a number of 
potential benefits over lesion directed therapy, such as better over all clearance with limited 
local skin responses and better cosmetic results. Because of the important advantage to 
treat subclinical lesions, it is therefore advised to treat areas, rather than solitary lesions.7 
Currently, there is insufficient information in literature considering the risk of developing 
SCC in a pre-existing AK.  Several studies state percentages varying between 0.025% - 16% 
per AK lesion per year.1,2,8 Because of this uncertainty, the Dutch guideline for actinic kera-
tosis advises to treat all AK.9   There are however several treatment options, with variable 
(cosmetic) result and side effects. 
Cryotherapy with liquid nitrogen is the most widely used therapy for actinic keratosis.10 
For solitary AKs cryosurgery is an effective, easily performed and cost-effective treatment. 
However, for field treatment cryotherapy is painful and may be associated with high recur-
rence rates.11 Both national and international guidelines consider cryotherapy not to be 
a preferred treatment modality for field treatment.12,13 9,14 There is a number of (placebo) 
controlled studies that compare different field-treatments, such as photodynamic therapy 
(PDT), topical 5-fluorouracil (Efudix), topical Imiquimod (Aldara), chemical peelings and 
laser surgery.  However, treatment protocols and outcome parameters differ to a great 
extent. Moreover, follow-up periods often are limited. Many comparative trials are industry 
sponsored and give inconsistent results. Some studies strongly favor 5-fluorouracil over 
Imiquimod, while others give quite the opposite results. For that reason, those studies are 
an inadequate basis to come to an evidence based choice of treatment.  
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At the moment 5-fluorouracil and PDT are the two most commonly used treatments in 
the Netherlands.15  However, the current Dutch guideline for AK does not recommend 
either those as a preferable treatment. 16 Hence, which treatment the patient will receive, 
generally relies on the preference of the physician instead of evidence based medicine.
In 2012 Gupta et al. concluded in their Cochrane systematic review, that more direct com-
parisons between frequently used field treatments are needed to determine the best 
therapeutic approach for patients with AK.17 The most recent data to approach this question 
more explicitly, are provided very recently by the same group, who performed a network 
meta-analysis  of eight interventions for AK as a follow-up of their Cochrane review (cryo-
therapy, topical Diclofenac 3%, 5-aminolevulinic acid (ALA) photodynamic therapy (PDT), 
5-fluorouracil (5-FU) 0.5% or 5%, Imiquimod (IMI) 5%, Ingenol mebutate (IMB) 0.015%-0.05%, 
methyl-aminolevulinate (MAL)-PDT and placebo/vehicle).18   Interventions were eventually 
ranked as follows: 5% 5-FU > 5-aminolevulinic acid(ALA)-PDT ≈ Imiquimod 5% ≈ Ingenol 
Mebutate (IM) ≈ Methylaminolevulinate (MAL)-PDT > Cryotherapie > Diclofenac 3%. Con-
sequently, based on this outcome 5% 5-FU  should be the treatment of choice.  However, 
this statement has never been investigated in a prospective randomized controlled trial. 
General advantages of network meta-analyses over standard pairwise meta-analysis is that 
it facilitates indirect comparisons of multiple interventions that have not been studied in a 
head-to-head fashion.  However, an important limitation of network meta-analyses in gen-
eral is that they are perceived to be more complex and prone to misinterpretation. 
In this article, the most frequently used therapies for field-AK are described and results 
are outlined in Table 1-4. There is a large heterogeneity in the outcome measures used 
in the different studies. 
Search and results
The PubMed and Cochrane databases were searched (august 1976 – march 2014). The 
following search terms (including derivates) were used:  actinic keratosis, solar keratosis, in 
combination with: treatment, randomized controlled trial, clinical trial, review. Further eligible 
publications were found from reference lists. 
Cryosurgery
Cryosurgery or cryotherapy is the application of extreme cold liquid nitrogen, to destroy 
diseased tissue. The nitrogen is applied to the skin lesion for a few seconds, depending 
on the desired diameter and depth of freeze. Treatment is repeated once, the so called 
‘double freeze-thaw’.19
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Even though cryosurgery is a frequently used treatment, randomized controlled stud-
ies are lacking. Percentages of complete remission in solitary AK lesions, vary between 
75% and 98%.20 Recurrence of lesions is estimated between 1.2% and 25% of lesions at 
12 months follow-up.  Szeimies et al. compared methylaminolevulinate (MAL)-PDT with 
cryosurgery in 193 patients with a total of 699 AK’s. Complete response (CR) rates were 
assessed, resulting in 69% CR in MAL-PDT group versus 75% CR in cryosurgery group. This 
difference was not statistically significant. Both treatments were more effective for thin AK 
lesions (Olsen grade I, II) compared to thicker lesions (Olsen grade III). 21,22 Another study 
found that that the histologic clearance rate (32%) was considerably lower than the initial 
clinical clearance rate of 68%.23 These authors also found that histologic clearance rate 
was higher with topical therapy (Imiquimod and 5-FU) for AK lesions on the head, neck or 
décolletage. After 1 year only 4% of patients who underwent cryotherapy had a sustained 
clinical clearance. These low efficacy rates do not support widespread use of cryotherapy. 
Furthermore, cryotherapy is not a desired treatment for multiple or subclinical lesions.9,12-14 
Treatment generally causes a grade 2 burn wound and can cause extensive scarring when 
a large area is treated. 
Photodynamic therapy
Photodynamic therapy (PDT) is an in-hospital treatment in which either 5-aminolevulinic 
acid (ALA) or methyl-aminolevulinate (MAL) as topical agents are generally combined 
with a red non-cohorent light source. However, protocols vary and besides differences 
in photosensitizing agents, also different light sources, fractionation schedules, number 
of illuminations and pre-treatment modalities are described. MAL (metvix®) cream is the 
most frequently used topical photosensitizer in the Netherlands at the moment. Treat-
ment according to the standardized MAL treatment protocol (Galderma ®) is advised. 
5-ALA cream (Ameluz ®) is an alternative photosensitizer. Because there are no direct 
comparative studies between Metvix (MAL) and Ameluz yet. It is expected that they have 
the same efficacy, however the available 5-ALA studies use different formulations.
The cosmetic outcome after PDT treatment is usually excellent.  Because of the discomfort 
patients may have in case of the long-term application of other topical agents and conse-
quently the assumed poor compliance, many physicians prefer an in-hospital treatment. 
This is why in a significant amount of hospitals PDT is now the first-choice treatment.17,24 
However, PDT is more expensive and patients experience it as very painful, because of 
the burning sensation it causes. For this reason, patients often refuse further treatment. 
Placebo-controlled randomized trials with MAL-PDT show complete lesion response in 
69%-91%, 3 months post-treatment after one or two treatment sessions based on several 
clinical trials.20,21,25,26 A randomized trial performed by Tarstedt et al. assessed the efficacy 
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of 2 versus 1 illumination for MAL-PDT treatment. All lesions with non-complete response 
were treated a second time after three months. Results show that overall, one illumina-
tion is as effective as two (81% versus 87% response, p= ns), 3 months post treatment. 
Thicker and non-responding lesions do benefit from 2 illuminations (70% response after 
one illumination, compared to 84% after two illuminations).26 Thirty-seven (19%) lesions 
with a non-complete response after a single treatment were re-treated.  Follow-up lasted 
until 3 months after the last treatment. 
Unfortunately, many studies describe efficacy results based on two consecutive illumi-
nations, one week apart and non-responding lesions are treated again after 3 months. 
This is not the standard MAL treatment protocol for AK in the Netherlands, which makes 
the studies described above less representative for our daily practice. Negative effects of 
PDT are the prior mentioned local pain, duration of the treatment, and the costs. Major 
advantages are selectivity of photosensitizing agents (e.g. when compared to 5-FU) and 
the possibility for field treatment.
New in the field of PDT is daylight-PDT, in which a photosensitizing agent is combined 
with daylight instead of an in hospital, non-coherent light source.  Described advantages 
are less pain, patient comfort and lower costs. This treatment is not yet standard care in 
the Netherlands. 
5-Fluorouracil 
5-Fluorouracil (5-FU) is a topical chemotherapeutic agent. It is a well-known field directed 
treatment, which can be applied by the patient at home during 4 weeks twice daily.27 
Two different dosages (0.5% and 5%) are used. In Dutch practice only 5% 5-FU is regis-
tered.28 When treating localized disease, patient complete clearance rates of 43%-96% 
are described.16,23,29,30 Recurrence rates after 12-36 months vary from 43%-44%.28 These 
clinical trials do not describe a repetitive treatment after 3 months.
The majority of clinical trials so far have assessed the 0.5% dosage.  A randomized con-
trolled trial comparing topical 5% Imiquimod, 5% 5-FU and cryosurgery showed initial 
clearance rates of 85%, 96% and 68% respectively.23 After 1 year follow-up 28% of patients 
treated with cryosurgery had no residual or recurrence AK, compared to 54% in 5-FU 
group and 73% in Imiquimod group (p <0.01). A similar study comparing topical 5% 5-FU 
and 5% Imiquimod showed that 5% 5-FU is superior for field treatment. There was a reduc-
tion of final AK count (decline during 24-week follow-up) by 94% versus 66% in 5% 5-FU and 
5% Imiquimod groups respectively (p <0.05). Patient complete clearance was achieved in 
84% of 5% 5-FU patients compared to 24% of 5% Imiquimod patients (p < 0.01).31 Kurwa et 
al examined the efficacy of a single PDT illumination versus 5% 5-FU cream twice daily for 
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3 weeks in a randomized right/left comparison,  with no statistically significant difference 
between them.32 A systematic review found  that treatment with 5% 5-FU resulted in an 
average reduction of 79.5% in the mean number of lesions.33 Krawtchenko et al. showed 
no statistical difference in both clinical and histological clearance rate, between Imiquimod 
5% and 5% 5-FU at 3 months follow-up. 23
Imiquimod
5% Imiquimod is also often used for generalized treatment of more disseminated dis-
ease. A once daily application for 3 days per week during a 4 weeks schedule is needed. 
Consequently a 4 week period of no application follows. If there is residual AK, the same 
schedule of 4 weeks can be repeated. However, comparable to MAL-PDT studies the 
clinical studies reviewed do not mention what amount of residual AK is needed for this 
follow-up treatment. 
Several results considering the efficacy of Imiquimod have been described above. A study 
from 2005 showed a higher average patient complete clearance with imiquimod treatment 
(70% for Imiquimod versus 52% for 5-FU).34 However 0.5% 5-FU was used. A study by Kraw-
tchenko et al. showed a similar clinical and histological clearance rate between Imiquimod 
and 5% 5-FU, but Imiquimod had a superior sustained patient complete clearance rate at 
12-month follow-up (73% for Imiquimod and 54% for 5% 5-FU).23 However, the number of 
patients in each group was small. Alomar et al. studied 259 patients who were randomized 
for treatment with either 5%-Imiquimod or placebo. Imiquimod had a CR of 55%.35 In 2004 
Lebwohl et al. showed 45% patient complete clearance rate and 83.3% lesion reduction 
after 5% Imiquimod treatment.36 Follow-up duration however was only 2 months.  
Ingenol mebutate
Ingenol Mebutate (IM) gel is a novel topical product, FDA approved since January 2012 and 
approved by Dutch health care insurances since October 2013.28,37,38 IM is a pleotropic 
effector inducing cell death and activates the immune response and is an effective treat-
ment.39 IM gel is suitable for field treatment. The main advantage of treatment with this 
self-applicable gel, is a shorter duration of treatment (2-3 consecutive days, depending 
on the location of AK, applied by the patient) and therefore also a shorter downtime, 
compared to 5-FU.  This probably has a positive effect on the compliance. 
Lebwohl et al. were the first to describe the clinical efficacy of topical Ingenol Mebutate (IM) 
in a randomized placebo controlled trial. Pooled analysis of face and trunk areas showed 
42.2% of patients had complete patient clearance of AK at 8 weeks follow-up compared 
to 3.7% in placebo group (p <0.001). Partial clearance was observed in 63.9% for IM com-
pared with 7.4% in placebo group (p < 0.001). A median reduction of 83% from baseline 
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in the number of actinic keratosis treated with IM was observed. At long term follow up 
one year post-treatment, the sustained lesion reduction rates compared to baseline were 
87.2% for the face and scalp. For trunk and extremities this percentage was 86.8%.40
Conclusion
In conclusion, AK is a chronic skin condition with a high prevalence, which is expected to 
rise even further. There is a lack of good quality evidence to determine what is the best 
field treatment for AK.  There is a need for a multi-center randomized controlled trial 
that enables head to head comparison of frequently used treatments for AK in the same 
study population with at least 1 year follow-up.  Furthermore, the cost-effectiveness of 
treatments is not yet established in a large prospective trial.  Our group previously showed 
that an old cheap treatment (5% 5-FU) is not inferior to the expensive new treatment 
(PDT) for treatment of superficial basal cell carcinoma.41 This outcome will save the Dutch 
government millions each year. This issue and the expected cost-saving can be even larger 
in AK, since it is much more common than superficial basal cell carcinoma. 
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“Focus like a laser, not a flash light”
- Michael Jordan
Chapter 2.2 
Laser mediated photodynamic therapy: 
an effective alternative treatment 
for actinic keratosis?
J.P.H.M. Kessels, P.J. Nelemans, N.W.J Kelleners-Smeets, 
K. Mosterd, G.A.M. Krekels, J.U. Ostertag. 
Acta Dermato-Venereologica 2016; 96(3): 351-4
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Abstract
Photodynamic therapy (PDT) with light emitting diode (LED) illumination is a frequently 
used treatment modality for actinic keratosis (AK) with excellent cosmetic outcome. A 
major disadvantage is the high pain score. Illumination using the pulsed dye laser (PDL) 
has been suggested. The long-term efficacy is unknown. In this split face study, we pro-
spectively treated 61 AK patients, with both LED-PDT and PDL-PDT.  The mean change in 
number of lesions between end of follow-up and start of therapy was -4.25 (95% CI [-5.07; 
-3.43]) for LED-PDT and -3.88 (95% CI [-4,76; -2.99]) for PDL-PDT with a non-significant 
difference (p=0.258) of -0.46 (95% CI [-1.28;0.35]). The percentage decrease from baseline 
in total number of AK was 55.8% and 47.8%, respectively, at 12 months follow-up. VAS pain 
score was lower after PDL (mean 2.64) compared to LED illumination (mean 6.47). These 
findings indicate that PDL-PDT is an effective alternative illumination source for AK when 
pain is a limiting factor for regular LED-PDT.
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Introduction
Actinic keratosis (AK) is the most prevalent precancerous skin condition, resulting from 
chronic ultraviolet (UV) radiation exposure. It is predominantly located on chronically 
sun-exposed skin such as the head, neck and the dorsal aspects of the hands.1 Preva-
lence is especially high among individuals with fair skin type or among individuals taking 
immunosuppressant medication.2 Typically, multiple AKs co-exist in a photo-damaged area 
and recurrence tends to be high probably as a result of field cancerization.3,4 This stresses 
the need for (repetitive) field-directed treatments.
Several interventions are currently used for the treatment of AK. Liquid nitrogen cryo-
therapy is the most frequently used therapy worldwide.5 However, this is a lesion directed 
treatment and has limited use in areas of field cancerization. In contrast, field directed 
therapies have the potential to treat subclinical lesions resulting in lower recurrence 
rates.6,7 Among the most frequently used field therapies are topical 5-fluorouracil cream, 
imiquimod cream, ingenol mebutate gel, diclofenac gel and photodynamic therapy (PDT).8
The mechanism of PDT is based on the interaction between photosensitizing agents such 
as 5-aminolevulinic acid (5-ALA) or methyl-aminolevulinate (MAL) and a light source.9,10 For 
this purpose, non-coherent light emitting diodes (LED) are used in daily practice.11 
A major disadvantage of non-coherent light sources is high pain experience, especially 
in patients with multiple AK. As a result, this forms a major drawback for follow-up treat-
ments.12
Prior research aimed to optimize PDT by attempting to reduce pain, offer shorter treat-
ment duration and shorter down times. One example is illumination with a long-pulsed 
pulsed dye laser (LP PDL).13 Despite promising results regarding the equal efficacy with 
less side effects, it remains unclear whether this efficacy is maintained at long-term fol-
low-up.13-15 In our study, we compared treatment efficacy of LED-PDT and PDL-PDT with 
a long-term follow-up. 
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Methods
Patients
Participants were recruited and treated at a secondary dermatology referral center in the 
Netherlands. Inclusion criteria were age 18 years or older, Fitzpatrick skin type I-III and a 
clinical diagnosis of AK on the scalp and/or forehead (minimal area of 25 cm2). Exclusion 
criteria were suspicion for malignancy in the treatment area, the use of immunosuppres-
sive medication, any topical treatment in the past six months within the treatment area, 
known hypersensitivity for the photosensitizer or presence of other skin conditions in the 
treatment area. The study was approved by the local medical ethical review board.16 All 
patients gave their written informed consent.
Procedures
The total number of target lesions in the treatment area of each individual participant was 
scored. Lesion severity was assessed using the Olsen scale (1 = mild (slightly palpable, 
more easily felt than seen); 2 = moderate (moderately thick, easy to see and feel); 3 = 
severe (very thick AK)). Two clinically equal treatment areas were assigned. Subsequently, 
both areas were pre-treated with slight curettage, followed by methyl-aminolevulinate 
cream (Metvix, Galderma ®) application. Both areas were covered with an occlusive and 
light blocking tape. After 3 hours, all participants received PDL illumination on the left side 
of the treatment area (595 nm Pulsed Dye Laser, Vbeam, Candela Corporation®, Wayland, 
MA, 7 mm spot size, fluence 7 J/cm2, pulse duration 10ms, epidermal cooling with Dynamic 
Cooling Device (DCD spray/delay) 30/10ms, spots overlapping 50%) and regular LED illu-
mination on the right side (Aktilite, Galderma®, 37 J/cm2, 635 +/- 18 nm.
Outcome assessment
Follow-up visits were scheduled at 3, 6, 9 and 12. During each follow-up the number of 
target AK’s was calculated. Adverse events were recorded by questionnaires. Pain scores 
were assessed using a visual analogue scale (VAS 0-10).
Statistical analysis
The primary outcome measure was defined as mean change in number of lesions between 
baseline and 12 months follow-up. A t-test for paired samples was conducted to test 
difference in mean decrease between treatments. The sample size of this study with 57 
patients enabled detection of a between treatment difference (in mean decrease of AK 
lesions with a standard deviation of 3) of 1.6 or more with a power of 80%. 
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Other continuous outcomes were also tested for statistical significance with a t-test for 
paired samples. Differences in proportions between treatments were tested using the 
McNemar test for paired proportions.  All analyses were performed on an intention to treat 
basis. P-values smaller than or equal to 0.05 were considered as a significant difference.
Results 
Sixty-one male patients with a mean age of 73.7 years (range 57-87) and Fitzpatrick skin 
type I-III were included. Baseline characteristics are shown in table 1. A total of 1041 AKs 
(531 PDL, 510 LED) with a mean Olsen score of 2.02 and 2.07 for LED and PDL illumi-
nation respectively, were included. A total of 57 patients were treated and completed 
follow-up. The other four patients were lost to follow-up because traveling distance or 
because severe health problems restrained them from follow-up visits. One patient was 
not able to complete LED illumination, due to extensive pain sensation. This patient was 
subsequently treated with PDL illumination on both treatment areas, but was analyzed 
in the LED group. Two patients were illuminated with the same treatment regimen again 
at 3 months follow-up, because of no or little clinical response in both treatment areas. 
Efficacy
The mean decrease in number of lesions from baseline to 12 months follow-up was -4.25 
(95% CI [-5.07; -3.43]) for LED-PDT and -3.88 (95% CI [-4.76; -2.99]) for PDL-PDT. The 
negative sign indicates a decrease in number of AK lesions in both groups. Hence, the 
difference between treatments in mean number of lesions was -0.46 (95% CI [-1.28;0.35]) 
with a standard deviation (SD) of 3.04 (p = 0.258). 
The relative decrease in total number of lesions from baseline (as percentage of the 
number of AK lesions at baseline) was 47.8% and 55.8% for PDL and LED illumination, 
respectively, at 12 months follow-up. Table 2 shows all the relevant outcome measure-
ments. Figure 1 illustrates the percentage of patients with better, equal or worse efficacy 
of LED compared to PDL illumination. 
The McNemar test showed no significant difference in global clinical improvement between 
both treatment groups (p = 0.625). A total of 89.3% of patients showed clinical improve-
ment after PDL versus 92.9% after LED illumination. 
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Table 1. Relevant baseline characteristics for both pulsed dye laser (PDL) and light emitting 
diode (LED, Aktilite) illumination.
PDL (n=61) LED (n=61)
Age (y), mean ± SD 73.7 ± 7.5 73.7 ± 7.5
Sex 
Male 
Female
61 (100%)
0 (0%)
61 (100%)
0 (0%)
Fitzpatrick skin type
I
II
III
14 (22.9%)
45 (73.8%)
2 (3.3%)
14 (22.9%)
45 (73.8%)
2 (3.3%)
No. of lesions per patient
1-5
6-10
11-15
>15
14 (23%)
32 (52.5%)
11 (18%)
4 (6.5%)
17 (27.8%)
28 (46%)
13 (21.3%)
3 (4.9%)
Total No. of lesions 531 510
Baseline total AK lesions (mean ± SD) 8.70 ± 3.98 8.36 ± 3.79
Olsen grade (No. of lesions)
1
2
3
6 (9.8%)
45 (73.8%)
10 (16.4%)
9 (14.7%)
42 (68.9%)
10 (16.4%)
Lesion location
Scalp
Forehead
50 (82%)
11 (18%)
50 (82%)
11 (18%)
AK: actinic keratosis, SD: standard deviation.
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Table 2. Relevant outcome measurements for both light emitting diode (LED) and pulsed 
dye laser (PDL) illumination during follow-up. 
Baseline 3 months 6 months 9 months 12 months
LED Mean lesion decrease 
(95% CI)
- -4.93 
[-4.10; 5.76]
-5.17
[-5.97;-4.37]
-4.75
[-5.57; -3.93]
-4.25
[-5.07;-3.43]
Total number AK 510 197 183 204 225
Cured number AK - 313 327 306 285
Percentage decrease from 
baseline 
- 61.4% 64.1% 60.0% 55.8%
PDL Mean lesion decrease 
(95% CI)
- -5.11
[-5.80;-4.42]
-5.29
[-6.15;-4.43]
-4.61
[-5.44;-3.78]
-3.88
[-4.76;-2.99]
Total number AK 531 223 203 236 277
Cured number AK - 308 328 295 254
Percentage decrease from 
baseline 
- 58.0% 61.8% 55.6% 47.8%
AK: actinic keratosis, CI: confidence interval
Figure 1. Percentage of patients with better, equal or worse efficacy of light emitting 
diode (LED) compared to pulsed dye laser (PDL) illumination
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Side effects
VAS pain score after PDL was significantly lower than after LED with a mean VAS-score of 
2.64 (SD= 1.84) and 6.47 (SD = 2.17) for PDL and LED respectively. The mean difference 
(PDL minus LED) was -4.55 (95% CI = [-4.06;-5.05], p < 0.01). Mean treatment duration for 
PDL was 1.45 minutes, compared to a predetermined 7.23 minutes for LED illumination.
Table 3 demonstrates the percentages of patients who reported side effects. Burning sen-
sation was reported significantly more often after LED illumination compared to PDL. Two 
patients developed a local skin infection in the LED treatment area, which was subsequently 
treated with topical antibiotic ointment (Fucidin cream, 20 mg/g, Leo Pharmaceuticals, the 
Netherlands). The skin healed without any residual changes in both patients.
Patient preferences 
Of the patients treated with PDL illumination, 78.7% would definitely undergo this 
treatment again versus 32.8% of the patients treated with LED illumination (p < 0.01). 
Furthermore 4.9% of patients treated with PDL illumination would definitely not undergo 
another treatment versus 19.7% of the patients treated with LED illumination (p = 0.013).
Table 3. The frequency of adverse events 1 week post-treatment, 
Adverse event PDL, n (%) LED n (%) p-value*
Burning sensation 13 (21.3) 43 (70.5) < 0.001
Erythema 54 (88.5) 59 (96.7) 0.095
Crusting 3 (4.9) 11 (18.0) 0.033
Infection 0 (0) 2 (3.3) 0.248
* McNemar test for paired proportions
Discussion
PDL illumination is a quick, patient friendly and safe treatment for mild to moderate 
AK.13,14 To our knowledge, the present study is the first to demonstrate efficacy data with 
long-term follow-up. Our results indicate that both illumination sources result in a similar 
decrease of AK lesions between baseline and 12 months follow-up. 
The similar effectiveness of PDL and LED is consistent with other studies that reported 
results after shorter follow-up duration. Aleksiades et al. studied the use of LP-PDL (595 
nm) illumination after either 3 or 14 to 18 hours incubation time with topical 5-ALA cream.13 
They concluded that it is a safe and effective treatment, with minimal discomfort and rapid 
recovery times. Specifically, the mean percentage of lesions cleared after one treatment 
2.2  |   Laser m
ediated PD
T: an effective alternative treatm
ent for actinic keratosis?
57
at 8 months follow-up was 90.3%. However, the number of patients who completed the 
8-month follow-up was small and little information about statistical analyses is given.13,17-
19 Other studies with a 1-3 month follow-up period reported no difference in efficacy 
between LED and PDL. These results however cannot be compared with our study as 
they had a shorter follow-up period and were performed within a smaller population.14,15
The exact mechanism behind the PDT response is not fully known yet. PDT is mediated 
by oxygen dependent photochemical reactions. In epithelial neoplasms, the topical pho-
tosensitizer is metabolized into protoporphyrin IX (PpIX) following illumination with visible 
light.20 Excitation of photosensitizers such as 5-ALA or MAL results in formation of cytotoxic 
free radicals and singlet oxygen. These target cellular and mitochondrial membranes 
resulting in apoptosis and necrosis.14,21,22 It is hypothesized that by dividing light exposure 
into several shorter pulses, there might be time for tissue re-oxygenation. This principle 
can be seen in pulsed laser systems. PDL illumination does trigger apoptosis, but because 
there is time for re-oxygenation in between pulses, there might be less tissue ischemia. 
A paper by Togsverd-Bo et al. describes the amount of photobleaching – the depletion in 
photosensitizer fluorescence intensity - using different light sources. They conclude that 
LED produces significantly higher photobleaching compared with LP-PDL. The median 
photobleaching percentages of LED at a dose of 37 J/cm2 were 91% and 98%, compared 
to 43% and 52% after LP-PDL at 7.5 J/cm2. This might explain the lower pain experience 
during PDL illumination.23 
Pain is a major concern among physicians and a major drawback for patients to undergo 
new PDT treatments in the future. Our results show that pain scores are high following 
LED mediated PDT, while pain sensation during PDL illumination is significantly lower. Our 
results also indicate a higher patient preference for PDL over LED illumination.
In previous studies, several factors that might influence pain sensation during PDT have 
been described.24,25 The presence of a dynamic cooling device, fast operation speed and 
the ability to work with longer pulse durations with non-purpuric effects, all may contrib-
ute to lower pain sensation in patients after PDL illumination.17,18 Air-cooling for example 
reduces the level of pain sensation during illumination.26,27 However, the amount of PpIX 
photobleaching is reduced when for example air-cooling devices are used, which might 
influence efficacy.28 Wiegell et al. suggested that pain sensation was directly related to 
the amount of PpIX formation prior to illumination.29 Another hypothesis is that photo-
sensitizing agents are transported into peripheral nerve-endings, hereby triggering nerve 
stimulation.30,31 The presence of apoptosis and necrosis, together with an inflammatory 
reaction, presumably contributes to the burning sensation as well.  Beside a lower pain 
sensation, other studies do show that PDL illumination can result in side effects such 
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as erythema and burning sensation as well, albeit to a smaller extent.14,17,18 Our results 
support these observations.
Despite the possible benefit of pain reduction, shorter treatment duration and less 
adverse events, PDL illumination has various disadvantages that should be taken into 
account. Relatively high costs, the need for special supplies and expertise to use the 
device are the most important ones. Not every hospital has a PDL device present. Both 
PDL and LED illumination are in-hospital treatments. Several studies have been done to 
assess efficacy of daylight as illumination source for the PDT response with the supposed 
advantage of less pain during the procedure.32-35 These studies show non-significant dif-
ferences between the efficacy of daylight and LED illumination and report high patient 
satisfaction, less pain sensation and a better time,- and cost effectiveness. Daylight PDT 
is therefore also a good alternative in cases in which pain is a limiting factor. However, in 
Europe it cannot be performed throughout the year. PDL-PDT is therefore a good alter-
native in winter times. The shorter total duration of PDL-PDT compared to daylight-PDT, 
is also an advantage.
Limitation of the present study is the open label non-randomized study design and the 
fact that the patients and investigator were not blinded. Also, newly developed lesions 
post-treatment were not differentiated from persistent lesions in analysis. Besides the 
presence of side effects, the duration of side effects was not assessed. 
To conclude, AK is a chronic lifetime skin condition with frequent relapses. Our results 
show that PDL illumination can be performed rapidly, resulting in lower pain sensation and 
is an acceptable alternative illumination source when pain is a limiting factor for regular 
LED illumination.
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Supplementary methods
Study design 
The current study is a prospective, open-label study with split-face design. Patients were 
treated with pulsed dye laser (PDL) mediated photodynamic therapy (PDT) on the left side 
of the face and conventional light emitting diode (LED)-mediated PDT on the right side of 
the face as was predefined in the study protocol. Both treatments took place on the same 
day with an interval of 1 min. Treatment order was counterbalanced to control for order 
effects. This was done to prevent an effect of treatment order on pain score for example. 
The primary outcome measure was mean change in the number of lesions between 
baseline and 12-month follow-up. Secondary outcome measures were pain sensation, 
qualitative clinical improvement and adverse events. 
Patients 
Participants were recruited and treated at the dermatology department of a secondary 
dermatology referral center in Eindhoven, the Netherlands, between November 2011 
and August 2012. Patients were considered eligible if they were 18 years or older, had 
Fitzpatrick skin type I–III and a clinical diagnosis of actinic keratosis (AK) on the scalp and/
or forehead. The AK had to cover a minimal area of 25 cm2 with the potency to be divided 
into 2 equal halves. The diagnosis was based on clinical assessment. Exclusion criteria 
were suspicion for malignancy in the treatment area, the use of immunosuppressive 
medication, topical treatment of any kind in the past 6 months within the treatment area, 
known hypersensitivity for the photosensitizer or presence of other skin conditions in 
the treatment area. The study was performed in accordance with the principles of the 
Declaration of Helsinki and approved by the local medical ethics review board (16). Prior 
to enrolment, all patients gave their written informed consent. 
Procedures 
At baseline the total number of target lesions in the treatment area of each individual 
participant was scored. Furthermore, lesion severity was assessed using the Olsen scale, 
based on the thickness of AK: 1 = mild (slightly palpable, more easily felt than seen); 2 = 
moderate (moderately thick, easy to see and feel); 3 = severe (very thick and/or obvious 
AK). Color photographs were taken from the treatment area at baseline and at each 
follow-up visit. Furthermore, patients’ concomitant medication and skin type according 
to the Fitzpatrick 6-point scale were registered. When the inclusion criteria were met, 2 
clinically equal treatment areas were assigned. Subsequently, both areas were pre-treated 
with slight curettage of hyperkeratotic lesions, followed by methyl-aminolevulinate cream 
(Metvix®, Galderma Benelux, Rotterdam, The Netherlands) application. Both areas were 
covered with an occlusive dressing (Tegaderm®, 3M Health Care, Amsterdam, The Neth-
62
erlands), a gauze, tinfoil and light-blocking tape, in order to increase penetration of the 
photosensitizer and prevent light exposure. After a 3-h incubation time, the cream residue 
was removed. Subsequently, all participants received PDL illumination on the left side of 
the scalp and/or forehead (595 nm Pulsed Dye Laser, Vbeam, Candela Corporation®, 
Wayland, MA, USA, 7-mm spot size, fluence 7 J/cm2 , pulse duration 10 ms, epidermal 
cooling with Dynamic Cooling Device (DCD spray/delay) 30/10 ms, spots overlapping 50%) 
and regular LED illumination on the right side (Aktilite®, Galderma), 37 J/cm2 , 635 ± 18 
nm, cooling was obtained with the incorporated fan. During illumination of either one of 
the areas, the other adjacent area was covered with occlusive dressing to prevent light 
exposure. Time required for both illuminations was registered. Because of the treatment 
nature patients were not blinded for treatment. 
Outcome assessment 
Follow-up visits were scheduled at 3, 6, 9 and 12 months post-treatment and were per-
formed by the same investigator (JK). During follow-up, the remaining number of target 
AKs were calculated. Moreover, global clinical improvement in AK post-treatment was 
scored in a qualitative way as no clinical improvement vs. clinical improvement. In case 
of no treatment effect or an increase in AK after treatment, the same treatment(s) were 
repeated. When a histologically confirmed skin malignancy was confirmed within the 
treated area, this was registered. Patients were asked to complete a detailed diary in 
which they recorded adverse events (erythema, crusting, infection and burning sensation) 
during the first 2 weeks post-treatment. In this diary, concomitant medication, such as 
antibiotic treatment, used within 2 weeks after treatment, was registered. Pain scores were 
assessed immediately after both treatments using a visual analogue scale (VAS) ranging 
from 0 (no pain at all) to 10 (worst pain imaginable). 
Statistical analysis 
The primary outcome measure was defined as the mean change in the number of lesions 
between baseline and 12-month follow-up. The decrease in number of AK lesions per 
patient in the treatment area was calculated. A t-test for paired samples was conducted 
to test the difference in mean decrease between treatments. The sample size of this 
study with 57 patients enabled detection of a between-treatment difference (in the mean 
decrease in AK lesions with a SD of 3) of 1.6 or more with a power of 80%. Other continu-
ous outcomes were also tested for statistical significance with a t-test for paired samples. 
Differences in proportions between treatments were tested using the McNemar test for 
paired proportions. All statistical analyses were performed on an intention-to-treat basis. 
Data were collected and analyzed with SPSS (version 19.9 for Windows). p-values smaller 
than or equal to 0.05 were considered as a significant difference.  
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“Look deep into nature and you will understand everything better” 
- Albert Einstein
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Abstract
Topical sinecatechins 10% ointment is known for its anti-viral properties, anti-proliferative 
effects and induction of apoptosis. It is suggested that the active constituent – EGCG – has 
anti-tumoral effects. We aimed to assess whether topical sinecatechins 10% ointment 
could lead to histological clearance of superficial basal cell carcinoma (sBCC) and we 
assessed whether it influences proliferation and apoptosis.
In this randomized, double blind, placebo-controlled trial, 42 patients were assigned 
to sinecatechins or placebo-ointment, which was applied for 6 weeks. All tumors were 
excised after 8 weeks. Histological tumor clearance and adverse events were evaluated. 
To determine the effect of sinecatechins on proliferation and apoptosis, we assessed the 
proportion of patients with decreased immunohistochemical expression of Ki-67 and Bcl-2 
between excision and baseline biopsy. 
Complete histological tumor clearance was seen in 1/21 (4.8%) and 2/21 (9.5%) patients 
of the sinecatechins and placebo group respectively (p >0.99). Decrease in Bcl-2 expres-
sion was observed more frequently in the sinecatechins group than in the placebo group 
(respectively 41.2% vs 23.5%, p = 0.163) and decrease in Ki-67 occurred in similar propor-
tions (31.3% versus 29.4%, p = 0.909). The sinecatechins 10% ointment led to more local 
skin reactions compared to placebo. 
We found no therapeutic effect of topical sinecatechins 10% ointment in treatment of 
sBCC. 
This trial is registered on clinicaltrials.gov (NCT02029352). 
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Introduction
The rising incidence of basal cell carcinoma and the extensive workload this entails, creates 
a need for non-invasive, self-applicable treatments.1,2 Superficial basal cell carcinomas 
(sBCC) grow down from the epidermis in the superficial dermis, making them accessible 
for topical treatment. However, tumor-free survival rates following topical treatments such 
as photodynamic therapy (PDT), imiquimod cream or 5-fluorouracil cream, are significantly 
lower than after surgical excision.3,4 Thus, the search for a more effective non-invasive 
topical treatment is ongoing.
The exact molecular mechanism of BCC development remains to be clarified. Almost 90% 
of sporadic BCC have identifiable mutations in at least one allele of the patched 1 (PTCH 
1) gene, an inhibitor of the Hedgehog (HH) pathway.5 There is also some evidence that the 
Wingless (Wnt) pathway might be a component for development of HH pathway-driven 
neoplasia such as BCC and that there might be some cross-talk between both pathways.6-8 
In physiological circumstances, the Wnt pathway initiates hair bud formation and HH sig-
naling subsequently promotes the proliferative expansion of follicle epithelium required 
for a mature follicle.6 Deregulation of the Wnt pathway causes accumulation of nuclear 
β-catenin protein, which then leads to tumor proliferation through activation of Tcf/LEF 
transcription factors.9
The active constituents of green tea may be promising in the treatment of BCC because 
of their supposed anti-carcinogenic effects as described by several cell culture and animal 
studies.10,11 Particularly the catechin epigallocatechin-3-gallate (EGCG) is considered an 
useful active constituent. It is assumed that it has a cytotoxic effect on skin cancer cells, 
inhibits cell growth and induces apoptosis.12,13 Furthermore there is evidence that EGCG 
might play a role in inactivation of β-catenin signaling of the Wnt pathway.12 In case of 
crosstalk between HH and Wnt signalling in BCCs, this effect of EGCG on β-catenin might 
indicate a target for BCC therapy.14,15 Other studies demonstrate that EGCG causes 
an apoptotic effect by decreasing Bcl-2 expression.16-18 EGCG has also been shown to 
decrease the expression of Cox-2, an enzyme involved in prostaglandin (PG) synthesis 
which is known to be elevated in BCC.19
Sinecatechins 10% ointment is an extract of green tea leaves of the Camellia sinensis spe-
cies and contains EGCG. It is currently used in the treatment of condylomata acuminata 
(CA)20,21 where it is known to have anti-viral properties, inhibits signal transduction and 
proliferation, and induces apoptosis.22-24 
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In this study, we aimed to assess whether topical Sinecatechins 10% ointment is effective 
in treatment of sBCC. We hypothesized, that topical Sinecatechins 10% application could 
lead to histological tumor clearance of sBCC. Furthermore, immunohistochemical stain-
ings were used to assess expression of Ki-67 and Bcl-2. Ki-67 is a well-known proliferation 
marker.25,26 Bcl-2 is a proto-oncogene, encoding a large anti-apoptotic cytoplasmic protein. 
27,28 Both stainings have been previously used to determine the effect of a therapy on pro-
liferation and apoptosis in BCC. To the best of our knowledge, there are no clinical trials 
on human subjects with topical EGCG on sBCC yet. 
Materials and methods
Protocol
We performed a double blind, randomized, placebo-controlled clinical trial at the Maas-
tricht University Medical Center+ (MUMC+), the Netherlands. Patients were recruited 
between November 2014 and September 2015 at the outpatient dermatology depart-
ment. 
Patients were eligible to participate if they had a primary, histologically proven sBCC with 
a diameter between 4mm and 20mm. sBCC was defined as small buds of basal cells 
with large, relatively uniform nuclei, growing down from the epidermis into the superficial 
dermis, whilst maintaining their attachment to the base of the epidermis.29,30 One sBCC 
per patient was included to ensure independence of observations. If patients had more 
than one sBCC, the tumor with the most accessible location and / or largest diameter was 
chosen. Patients were excluded if they had a sBCC located in the H-zone (high risk zone in 
the face) or on the hairy scalp, were using immunosuppressive drugs or had genetic skin 
cancer disorders. Breast-feeding and pregnant women were also excluded. 
The study was performed in accordance with the Declaration of Helsinki. The protocol 
was approved by local ethics committee (MUMC+) and registered on www.clinicaltrials.
gov (NCT02029352). All patients provided written informed consent. 
Outcomes
The primary outcome was the proportion of patients with complete histological tumor 
regression in the excision specimen post-treatment. Secondary outcomes were (1) pro-
portion of patients with decreased expression of Ki-67 and Bcl-2, (2) change in tumor size 
pre- and post-treatment, (3) adverse events and (4) compliance. The change in immuno-
histochemical expression between the excision specimen and the biopsy specimen was 
categorized as increased, equal or decreased compared to baseline. 
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Data on compliance were obtained from the personal diary and compliance was calculated 
as number of actual applications divided by the number of prescribed applications. To 
assess the adverse events during treatment a subdivision in two categories was made: 
absent/mild or moderate/severe. We evaluated the proportion of patients with moderate 
to severe adverse local reactions. 
Histopathologic assessment
From both biopsy and excision specimen, haematoxylin and eosin (HE) histological sec-
tions were obtained. We used immunohistochemical stainings to indicate the proliferative 
activity (Ki-67) and anti-apoptotic activity (Bcl-2). The immunohistochemical stains were 
prepared according to the laboratory protocols of the Department of Pathology, MUMC+. 
Stains were performed on 4 µm formalin fixed and paraffin embedded (FFPE) tissue sec-
tions of both biopsy and excision specimens using a Dako Autostainer Link 47TM (DAKO 
corporation, Carpinteria, CA, USA).  The primary antibodies used were Ki-67 (IR614, clone 
MIB-1, mouse monoclonal, ready to use Antibody, DAKO) and Bcl-2 (IR626, clone 124, 
mouse monoclonal, ready to use Antibody, DAKO). For each immunohistochemical stain-
ing, all tissue specimens were stained in one session to prevent differences in staining 
intensities between the samples. Positive and negative controls were used. 
All HE specimens were independently assessed by two dermato-pathologists who were 
blinded to treatment allocation, to evaluate presence of residual tumor and completeness 
of the excision. All HE slides were reviewed to assess which part of the excised specimen 
contained the largest amount of tumor. Consecutively the corresponding part of the par-
affin block was further sliced and used for immunohistochemical staining. The slide with 
the largest amount of tumor visible and the highest staining intensity was chosen for 
further assessment, in order to assess the most representative part of the tumor. From 
each selected slide of both biopsy and excision specimens a photograph was taken using 
a Leica DFC320® digital camera that was attached to a Leica DM3000 microscope, while 
using a 10x objective. All images were stored as tagged image file (TIF). 
Two trained investigators blinded to treatment allocation used all immunohistochemistry 
specimens to assess whether there was an increase, decrease or equal staining intensity 
when comparing expression of Ki67 and Bcl2 in the pre-treatment biopsy with expression 
in the post-treatment excision specimen. In case of disagreement between the investiga-
tors, consensus was reached. 
Assignment and masking
Patients were randomized to either intervention or placebo using a computer-generated 
randomization list using random permuted blocks of four. Patients and investigators, 
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including the assessing pathologists, were blinded to treatment assignment until the end 
of the study. Sinecatechins 10%,- and placebo ointments were provided by Will Pharma 
B.V (Zwanenburg, the Netherlands). All study medication was labeled according to good 
manufacturing practice (GMP) guidelines with pre-assigned study numbers. Labeling of 
study medication was performed by the trial pharmacy of the Radboud university med-
ical center Nijmegen. The vehicle of the placebo was equal to that of the sinecatechins 
10% ointment. Additionally, the placebo contained colorants such as titanium dioxide, 
red iron oxide and yellow iron oxide, resulting in a color and consistency identical to the 
sinecatechins 10% ointment. To ensure blinding both ointments had an identical package.
Participant flow and follow-up
After patients gave their written informed consent, tumor size was measured and stan-
dardized photographs were taken during the first study visit. Consecutively, patients 
received the study ointment. Patients were instructed to apply the ointment in a thin 
layer to the tumor, including 5 mm of surrounding healthy skin, twice daily (morning and 
evening) for six weeks.
Patients returned for follow-up visits in week 3 and week 6 after treatment. All tumors were 
removed by surgical excision with a 3 mm margin in week 8 during the final study visit. 
During the follow-up visits, tumor size and local skin reactions were assessed by the coor-
dinating investigator. Patients reported on skin reactions once a week in a personal diary 
they received at the first study visit Severity of skin reactions during treatment (i.e. redness, 
swelling, erosions, crusts, vesicles, squamae, itching and tingling) were scored as absent, 
mild, moderate or severe. Compliance data were also obtained from the personal diary. 
Statistical analysis
It was assumed that about 5% of sBCCs in the placebo group will show histological com-
plete tumor regression in the excision specimen, because of a possible biopsy-induced 
tumor regression 31. At least 50% in the sinecatechins 10% group had to show a complete 
tumor regression to consider this treatment as sufficiently effective for further evaluation. 
Based on an alpha=5%, and power of 80%, we calculated that a total of 38 patients (19 
patients per group) would be required. To account for a loss-to-follow-up of 10%, a total 
of 42 patients (21 patients per group) had to be included.  
Difference in proportions between the randomized groups was tested for significance 
using the Chi-square test or Fisher exact test (e.g. proportion of complete regression, pro-
portion with decreased expression of tumor markers, adverse events). Mean continuous 
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variables (e.g. tumor diameter, compliance percentages) were compared between groups 
and tested for significance using the T-test for independent samples (when normally dis-
tributed) or the Mann-Whitney U test (when not normally distributed). Reported two-sided 
P values ≤ 0.05 are considered statistically significant. Statistical analysis was performed 
with SPSS version 23.0 software (SPSS, Chicago, IL, U.S.A).
Results
Between November 2014 and September 2015, 89 patients were approached to par-
ticipate in the trial. A total of 42 patients were considered eligible and were willing to 
participate. They were randomly assigned to treatment with sinecatechins 10% or placebo. 
There were no major differences between both treatment groups. A total of 19 patients 
in the sinecatechins 10% and 20 in the placebo group completed the six weeks of study 
treatment. The primary endpoint was available for all randomized patients. 
Tumor clearance
Complete histological tumor clearance was seen in 1/21 (4.8%) and 2/21 (9.5%) patients 
of the sinecatechins 10% and placebo group respectively (p >0.99). 
Median decrease in tumor size between baseline and end of study was 0 mm (range -10 
to +5) for placebo and -1.50 mm (range -14 to +3) for the intervention group (p = 0.153).
Immunohistochemical evaluation
Figure 1 presents the proportion of patients with decreased expression of Ki-67 or Bcl-2. 
Complete data on Ki-67 and Bcl-2 were available for 33 and 34 patients, respectively. Not 
all tumors could be evaluated due to technical difficulties. Decrease in Bcl-2 expression 
was observed slightly more frequently in the sinecatechins 10% group than in the placebo 
group (respectively 41.2% vs 23.5%, p = 0.163) and decrease in Ki-67 occurred in similar 
proportions in both groups (29.4% versus 31.3%, p = 0.909). None of these differences 
were statistically significant. 
Adverse events
One patient in the placebo group reported pain during treatment, compared to four 
patients (20%) in the sinecatechins 10% group. Most local skin reactions occurred in the 
sinecatechins 10% group in the fourth week of treatment and decreased afterwards. 
In week 4 there was a significantly higher proportion of patients reporting moderate to 
severe erythema (60% vs 10%, p = 0.004), edema (30% vs 0%), p = 0.029), erosions (35% 
vs 0%, p = 0.014), crusts (50% vs 0%, p = 0.001) and itching (65 vs 0%, p< 0.001) in the 
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sinecatechins 10% group compared to the placebo group. Figure 2 demonstrates the 
percentage of patients who reported moderate to severe side effects during treatment. 
Analyses using investigator-reported side effects gave similar results. One patient in the 
sinecatechins 10% group reported flu-like symptoms, but completed study treatment. 
One patient in the same group stopped treatment in week 4 due to local skin reactions. 
None of the patients reported a serious adverse event.  
Figure 1: Proportion of patients (%) with decreased Ki-67 and Bcl-2expression post-treat-
ment, compared to baseline. 
Compliance
Median compliance was 100% in both groups, with a range of 83-100% in the placebo 
group compared to 65-100% in the intervention group. 
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Figure 2. Percentage of patients with moderate-severe local skin reactions, during treat-
ment, n (%) for placebo group and sinecatechins 10% group.
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Discussion 
The current study was the first to assess clinical efficacy of topical sinecatechins 10% oint-
ment in the treatment of sBCC. Our results show that there was no significant difference 
in histological tumor clearance between the sinecatechins 10% and the placebo group. In 
the intervention and in the placebo group, complete tumor remission occurred in 1 and 2 
patients, respectively, possibly reflecting a biopsy-induced immune response. 31 Decrease 
in tumor size was slightly larger after sinecatechins 10% application than after placebo, 
but the difference was non-significant.
In the current trial we assessed the proportion of patients with decreased expression 
between baseline biopsy and excision specimen for Ki-67 and Bcl-2. Ki-67 is a proliferation 
marker, expressed in all cell proliferation phases, except G0.27 Apoptosis is regulated by 
Bcl-2, expressed in the majority of BCC.27,32 Both markers were used previously in stud-
ies to assess the efficacy of a therapy. 27,28,33,34 A decrease in the expression of Bcl-2 was 
found in a clinical trial assessing the effect of topical imiquimod application in BCC.27 No 
significant changes for Ki-67 were observed in the same trial. Brinkhuizen et al. found a 
significantly decreased Bcl-2 and Ki-67 expression in sBCCs treated with topical Diclofenac, 
compared to baseline.33 
In our study, a decrease in expression of Bcl-2 was observed slightly more frequently than 
in the placebo group. This difference was not statistically significant. We quite unexpect-
edly observed a decrease in Bcl-2 and Ki-67 expression in a proportion of patients in the 
placebo group. A previously hypothesized increase in apoptosis in biopsy induced tumor 
regression could play a role.31
A possible explanation for the observed lack of efficacy of the topical sinecatechins 10% 
in the current study might be insufficient EGCG uptake after usage of the current formula 
could explain the lack of efficacy of the topical sinecatechins 10% ointment in the current 
study. An in vitro and murine study by Fang et al. found that when EGCG was encapsu-
lated in liposomes with deoxycholic acid and ethanol, the drug deposition was increased 
significantly compared to administration of free EGCG.35
In 2011 Tjeerdsma et al. reported a clinical case of a patient with basal cell nevus syn-
drome (BCNS) achieving a temporary (one year) arrest of developing new BCC shortly after 
she was receiving green tea body wraps once a month.36 The wraps used in this clinical 
report consisted of green tea and four other plant extracts (ginger oil, algae, mustard oil 
and calendula oil). Whereas both brown algae and ginger have some anti-carcinogenic 
effects, green tea supposedly has the most powerful anti-carcinogenic capacity with epi-
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gallocatechine-3-gallate (EGCG) being the most active constituent.12,13,37-40 The suggested 
effect of green tea in this specific case was preventive rather than curative. Also in other 
studies, oral or topical administration of polyphenols in green tea has shown to reduce UV 
induced inflammation, photo-aging and immunosuppression.16,22,39 Smith et al found that 
β-catenin was overexpressed in UVB-exposed mouse skin and keratinocytes, suggesting 
that this could be a target for skin cancer prevention.18 However, the observed frequency 
of adverse events discourages preventive application with the current formula of the 
sinecatechins 10% ointment in the dosage we used in this trial (twice daily). 
In conclusion, the results of this study do not corroborate the hypothesis that treatment 
of sBCC with topical sinecatechins 10% provides an alternative to already available topical 
treatments. 
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Chapter 4 
Treatment of superficial basal cell carcinoma: 
the role of PDT

“Luckily however, life doesn’t always follow tradition, but craves out a path of its own” 
- Kader Abdolah, The house of the mosque
Chapter 4.1 
Efficacy of 5-aminolevulinic acid PDT for the 
treatment of superficial basal cell carcinoma: 
a retrospective study
J.P.H.M. Kessels, J.C.J. Hendriks, P.J. Nelemans, K. Mosterd, N.W.J. Kelleners-Smeets
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Abstract
Background
There is limited literature on efficacy, using a twofold illumination scheme in ALA-PDT 
treatment for sBCC.
Objectives
To determine the efficacy of ALA-PDT for sBCC using a 2-fold illumination scheme after a 
single ALA application. Treatment failure within 12 months post-treatment was assessed.
Methods
In this retrospective case series and cohort study, electronic files from patients treated 
between January 2010 and August 2011 were reviewed. Follow-up data were gathered 
until March 2014. 
Results
A total of 323 sBCC were analyzed for recurrence. Cumulative probability of clinical recur-
rence free survival was 88.8% (95% CI [85.4; 92.4]), 81.8% (95% CI [77.3; 86.3]) and 77.1% 
(95% CI [71.0;83.6]) at 12, 24 and 48 months respectively. For histologically confirmed 
recurrences this was 90.2% (95% CI [86.9;93.5]), 85.4% (95% CI [75.5;89.3]) and 81.8% 
(95% CI [75.5;88.1]) respectively. A worse recurrence free survival for tumors in the head 
and neck area and tumors larger than 10 mm was observed.  
Limitations
The retrospective nature and the lack of a control group.
Conclusions
ALA-PDT using a twofold illumination scheme might be a feasible treatment option with 
acceptable long-term results for small sBCC located outside the head and neck area.
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Introduction
Basal cell carcinoma (BCC) is the most common skin cancer in Caucasians, with a rapidly 
increasing incidence.1-5 The estimated annual percentage of change between 2002 and 
2009 was 6.8% for men and 7.9% for women in the Netherlands.4 Histologically, BCC may 
be subdivided into three subtypes: superficial, nodular and infiltrative.6 Around 9% to 43% 
of BCC has a mixture of histological subtypes.7,8 The most prevalent subtype is the nodular 
BCC.9,10 Interestingly, a rise in the relative proportion of the superficial type of BCC (sBCC) 
has been observed, with an increase from 18% to 31% in the last 20 years.11,12 This rise is 
especially seen in young women.13
Treatment by surgical excision has the lowest recurrence rate and therefore remains the 
gold standard for most BCC. Recurrence rates vary from 2-8% 5 years after surgery.14-16 
Surgical procedures however, tend to be invasive and lead to scar formation. 
A prior study by Flohil et al. showed a linear increase of 6.3% in the incidence of BCC in 
women below the age of 40 years, since 1973. 17 Because of the increasing number of 
younger patients, cosmetic outcome is an important factor in treatment choice. Despite 
lower efficacy compared to surgery, alternative treatments such as cryotherapy, photo-
dynamic therapy (PDT), topical imiquimod and 5-fluorouracil, are also frequently used.18,19 
PDT is especially known because of its excellent cosmetic outcome and the advantage of 
an office-based treatment, which ensures compliance.18,20-22 It combines the use of topical 
porphyrin precursors as photosensitizers followed by illumination with visible light. Currently 
two topical precursors are used. 5-Aminolevulinic acid (ALA) was first approved by the Food 
and Drug Administration (FDA) in 2001. The more lipophilic methyl-aminolevulinate (MAL) 
was registered in most European countries for sBCC and actinic keratosis (AK) in 2004 and 
for the treatment of Bowen’s disease in 2006.23 It is not available in the United States. 
Although PDT is an effective treatment, a systematic review by Roozeboom et al. described 
a recurrence rate of 16% in sBCC, based on pooled estimates at 12 months post-treatment 
when assessing both ALA and MAL-PDT and different light sources.19 In order to improve 
its efficacy de Haas et al. developed a 2-fold illumination ALA-PDT protocol. Instead of the 
regular treatment scheme for sBCC using a fluence of 75 J/cm2 4 hours after administration 
of 5-ALA, two illuminations were used with 20 and 80 J/cm2, delivered respectively 4 and 
6 hours after one single 5-ALA administration. 24 In this study, a recurrence rate of only 
3% was reported 12 months post-treatment. This new, 2-fold illumination 5-ALA protocol 
was implemented in daily practice in our hospital. The present study evaluates the risk 
of recurrence after this 5-ALA PDT treatment and aims to identify prognostic factors for 
recurrence.
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Methods
Patients
After receiving approval from the local ethical committee, patients were recruited retro-
spectively by performing a search within our electronic patient system at the department 
of Dermatology, Catharina hospital Eindhoven, the Netherlands. This identified all patients 
treated with PDT between January 1st 2010 and August 31st 2011. Consecutively, all these 
electronic patient files were reviewed. Included were patients with histologically confirmed 
sBCC that were treated with the 5-ALA PDT protocol using a twofold illumination between 
January 1st 2010 and August 31st 2011. Exclusion criteria were previous treatment of the 
index sBCC, absence of histological confirmation prior to treatment, other histological 
subtypes apart from superficial BCC in case biopsy was taken, genetic disorders causing 
skin cancer and immunosuppressive drug-use at time of treatment. The same examiner 
reviewed all patient files.  In case a patient decided to end follow-up or consult a derma-
tologist in another facility for follow-up, we did not have access to these patient records. 
Results of these few patients were analyzed until their last moment of follow-up. If a 
patient had multiple eligible sBCC, the first reported tumor was included for analysis to 
ensure independence of observations. If reported, age, sex, Fitzpatrick skin type, number 
of tumors and dates of outpatient visits were recorded for all patients. Consecutively 
histology, localization and size were recorded for each tumor. Retrospective review of all 
patient files was completed on March 1st 2014. 
Design
This single center study describes the 1-year probability of recurrence free survival in a 
case series. For the evaluation of factors that are prognostic for treatment failure, the 
study can be considered a cohort study, wherein potentially relevant prognostic factors 
represent exposure status (tumor size, tumor location etc.). Exposure groups are com-
pared with respect to the probability of treatment failure. 
All patients were treated with topical 20% 5-ALA cream. This was prepared using 20% 
5-ALA (FLUKA, the Netherlands) in Neribas® (Bayer, Leverkusen, Germany) cream, pre-
pared by the hospital pharmacy.25-27 Before treatment, excessive scaling was removed 
by curettage using a wooden spatula. 5-ALA cream was then applied on the lesion with 
a margin of 1 centimeter and a thickness of 1-2 millimeters. Consequently, the treat-
ment area was covered with a semi-permeable dressing (Tegaderm ®, 3M Healthcare, 
Leiden, the Netherlands), a gauze and aluminium foil in order to prevent light exposure. 
After a period of 3.5 hours, the occlusive material was removed, excess cream was gently 
removed and illumination took place, using a 630 nm light source (Aktilite, Galderma®, 
the Netherlands). A total light dose of 20 J/cm2 was accomplished in 4.23 minutes. Subse-
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quently, the treatment area was covered again with Tegaderm®, a gauze and aluminium 
foil for 2 hours, whereupon a second illumination of 18.8 minutes and a light dose of 80 
J/cm2 took place. This resulted in a PDT treatment with two illuminations on the same day 
with a total light dose of 100 J/cm2. 
Whenever burning sensation during treatment was too intense, wet gauzes were used 
to cool the skin. In accordance with the treatment protocol, this was allowed not prior 
to 2 minutes after initiation of the illumination. In case of excessive pain sensation, the 
treatment site could be locally infiltrated with a Lidocaine 2% without epinephrine injec-
tion. After the second illumination, a cooling ointment (Unguentum Leniens) was applied 
to the treated site. All patients were recommended to use the cooling ointment after 
the treatment, until the burning sensation ceased. Patients were advised to avoid direct 
sunlight two days post-treatment. 
Statistical analysis
The primary outcome measure was the proportion of treatment failure within 12 months 
post treatment. Time-to-event analyses were used to take into account differences in fol-
low-up between patients and success of treatment was presented in terms of recurrence 
free survival. Kaplan-Meier survival analysis was performed to calculate the cumulative 
probability of recurrence free survival at 12, 24 and 48 months post-treatment.28 
Cox proportional hazards regression models were utilized to evaluate the independent 
effects of patient and tumor characteristics such as age, gender, tumor localization and 
tumor size on probability of recurrence. Hazard ratios with 95% confidence intervals asso-
ciated with prognostic factors were calculated. The proportional hazards assumption was 
tested graphically and with use of Schoenfeld residuals.  
All analyses were performed using SPSS version 21 (IBM statistics, U.S.A) and STATA 
version 11.0 (STATA Corp, College Station, TX, U.S.A). A two-sided p-value of <0.05 was 
considered as statistically significant.
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Results
A total of 379 patients with 562 sBCC’s were treated with the described twofold ALA-PDT 
protocol between January 2010 and August 2011. A total number of 56 patients were 
excluded from analysis because of loss to follow-up directly after treatment (n=6), lack of 
histopathological confirmation of the diagnosis prior to treatment (n =17) and the index 
BCC being a recurrent tumor (n=33). A total of 323 patients remained for analysis. Of these 
patients, 223 (69%) had one sBCC and 31% had more than one sBCC. 
The majority of sBCC’s were located on the back (n=96, 29.7%) and chest / abdomen 
(n=72, 22.3%) (Table 1). Tumor size was dichotomized into: ≤ 10 mm or > 10 mm diameter. 
More than half of all included tumors were less than or equal to 10 mm (n=165, 51.1%). 
A minority had a size larger than 20 mm (n=9, 2.8%).
The median follow-up time was 28 months (range 1-48), with 192 patients (59%) having a 
follow-up period of more than 2 years. During follow-up visits, treatment failure was clini-
cally observed in 58 patients. In 46 patients, histopathological examination was performed 
and recurrence was histologically confirmed in 44 patients. The majority of histological 
subtype in case of recurrence was nodular (54%) and superficial (41%). In 12 cases the 
treating physician was convinced of a recurrent BCC or the patient refused biopsy, so 
histological confirmation was lacking in these cases. 
All patients completed both illuminations. Two patients received local anesthesia because 
of excessive pain during illumination. The cumulative probability of recurrence free survival 
was 88.8% (95% CI [85.4;92.4]), 81.8% (95% CI [77.3;86.3]) and 77.1% (95% CI [71.0;83.6]) 
at 12, 24 and 48 months respectively. When defining treatment failure as a histologically 
confirmed recurrence (leaving out clinically observed recurrences without histological 
verification) the 12 month cumulative probability of recurrence free survival was 90.2% 
(95% CI [86.9;93.5]). At 24 and 48 months, cumulative probabilities were 85.4% (95% CI 
[81.3;89.3]) and 81.8 % (95% CI [75.5;88.1]) respectively (Figure 1, Table 2).
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Table 1. Baseline characteristics
n (%)
Age (y), mean (range)
Sex
    Male
    Female
Fitzpatrick skin type
    I
    II
    III
    Unknown 
No. of lesions per patient
    1
    2
    3
    4
    ≥ 5
Location sBCC
    Head/neck area
    Upper extremity
    Lower extremity
    Back 
    Chest/abdomen
Size (mm) 
    < 10 
    10-20
    >20
    Missing 
63.6 (25-90)
156 (48.3)
167 (51.7)
80 (24.8)
128 (39.6)
21 (6.5)
94 (29.1)
223 (69.0)
65 (20.1)
21 (6.5)
7 (2.2)
7 (2.2)
52 (16.1)
49 (15.2)
54 (16.7)
96 (29.7)
72 (22.3)
165 (51.1)
100 (30.9)
9 (2.8)
49 (15.2)
Table 2. Cumulative probability of recurrence free survival for both clinically observed and 
histologically confirmed recurrences.
Follow-up time 
(months)
Proportion recurrence free 
survival histological recurrences (%), 
[95% CI]
Proportion recurrence free 
survival clinical recurrences (%), 
[95% CI]
3 95.8% [93.6;97.9] 95.0 % [94.8;95.2]
6 93.7% [90.9;96.4] 92.1% [91.8;92.4]
12 90.2% [86.9;93.5] 88.8% [85.4;92.4]
24 85.4% [81.3;89.3] 81.8% [77.3;86.3]
48 81.8% [75.5;88.1] 77.1% [71.0;83.6]
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Figure 1. Kaplan-Meier survival curve
Table 3 presents the hazard ratios for recurrence according to baseline characteristics 
(male-female, age groups ≤60 and > 60 years and tumor size > 10 mm and ≤ 10 mm). 
The test of the proportional hazard assumption was not significant for both clinical and 
histological recurrences (respectively p= 0.692 and p= 0.389). Tumor localization in the 
head and neck area is associated with a significantly higher risk of clinical treatment failure 
compared to tumor localization elsewhere (HR = 2.55 (95% CI [1.43;4.57], p = 0.002). In the 
head and neck area we found 8.3% superficial, 83.3% nodular and 8.3% infiltrative recur-
rent tumor subtypes. In the non-head and neck area these percentages were respectively 
53.1%, 43.8% and 3.1%.
Furthermore, a worse recurrence free survival was observed for large tumors (i.e. >10 
mm) compared to small tumors (HR = 1.81 (95% CI [1.07; 3.06], p = 0.026). When defining 
treatment failure as a histologically confirmed recurrence, the HR estimates were similar, 
but only tumor location in the head and neck area was associated with significantly higher 
risk of recurrence.
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Figure 2. Kaplan-Meier survival according to sex, tumor localization (head/neck versus 
other), tumor size (>10mm versus ≤ 10mm) and age (>60 versus ≤60).
2.1
2.2
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Figure 2. Continued.
2.3
2.4
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Table 3: Cox proportional hazard ratios for recurrence for sex, tumor location (head/
neck versus other), size (>10mm versus ≤ 10mm) and age (>60 years versus ≤60 years). 
* p-value <0.05
Clinically observed 
recurrences (n=58)
Histologically confirmed recurrences 
(n=44)
HR for recurrence
(95% CI)
p-value HR for recurrence (95% CI) p-value
Sex (female versus male) 0.85 [0.51; 1.43] 0.547 0.99 [0.54;1.79] 0.968
Tumor location
(head/neck versus non-head/neck)
2.55 [1.43; 4.57] 0.002* 2.44 [1.25; 4.76] 0.009*
Tumor size 
(>10mm versus ≤ 10 mm)
1.81 [1.07; 3.06] 0.026* 1.61 [0.89; 2.94] 0.117
Age (>60 vs ≤ 60) 0.59 [0.35; 1.00] 0.053 0.644 [0.35; 1.18] 0.155
Discussion
This retrospective study confirms prior observations, that using 20% 5-ALA PDT followed 
by a twofold illumination scheme might be an effective treatment modality for sBCC with 
a tumor free survival of approximately 90% after 12 months.  
When ALA was introduced as a topical photosensitizer, results were promising.29-31 In a sys-
tematic review, Peng et al. reviewed 12 studies in which sBCC were treated with ALA-PDT, 
and showed a weighted clearance rate (CR) of 87%.32 A more recent review by Roozeboom 
et al. described an overall CR of 79% at 12 weeks post-treatment based on pooled esti-
mates derived from 28 studies using both ALA as well as MAL as a photosensitizer. The 
majority of studies investigated ALA-PDT after a single illumination. Tumor-free survival 
was higher in studies that repeated illumination compared to a single illumination. This 
could indicate that repeated illumination results in improved clinical outcome.19 
There are only a few studies that report follow-up data of ALA-PDT after a twofold illumi-
nation scheme.23,24,33,34 Star et al. reported a pilot clinical study in 15 patients and found 
a CR of 88% at 12 months follow-up after twofold 5-ALA illumination (45 J/cm2 + 45 J/cm2 
separated by a two-hour dark interval).33 In a large prospective comparative study from 
the same group, the twofold protocol (20 + 80 J/cm2 with a two hour dark interval) was 
compared to single illumination (75 J/cm2). This resulted in a CR of respectively 97% and 
89% at two-year follow-up.23 At long-term follow-up (5 years), a CR of 88% is still observed 
compared to 75% after a single illumination.34 
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Our data show a CR comparable with Star et al. 12 months post-treatment. However, the 
CR of 97% described by de Haas et al. was much higher than our results, even though we 
performed the same two-fold illumination treatment. An important difference between 
both studies is the study design. The lower treatment success might be due to the ret-
rospective nature of our study. Even though this treatment is performed by a nurse/
physician and compliance is expected to be high, protocol deviations (e.g. the exact time 
between cream application and illumination) might not be reported as accurate as in a 
prospective study design.
The choice for a 2-fold illumination scheme is based on extensive pre-clinical research. 
Several studies, including mouse models, demonstrated re-synthesis of PpIX after a first 
illumination. Between two cycles of illumination there is time for tissue re-oxygenation. It is 
hypothesized that the heme synthesis cycle is still intact, which leads to further conversion 
of ALA into PpIX.35-38 This post-illumination increase in PpIX has both been observed after 
PDT with systemic and topical ALA.38-40 These observations might explain the described 
increase in PDT efficacy after a second illumination. The optimal time interval between 
both illuminations has also been studied extensively. Maximal PpIX concentration following 
ALA application was observed 6 hours after the end of the application time. A two-hour 
interval between both illuminations results in a significant increase in PDT response.24,37 
Compared to topical 5-fluorouracil cream and imiquimod cream for which the patient has 
to apply a cream for several weeks or MAL-PDT which includes 2 separate illuminations, 
the advantage of this 2-fold illumination is the fact that it is a one day treatment.
Results suggest that sBCC with a diameter smaller than or equal to 10 mm and sBCC 
that are located outside the head and neck area have a better recurrence free survival 
compared to tumors larger in diameter and located in the head and neck area. This is con-
sistent with other studies that showed an increased risk for recurrence in larger tumors 
and located in the mid-face and ears.41,42 In our sample there might have been more mixed 
tumor types in the head and neck tumors, which might also explain a worse outcome.
Across Europe, the lipophilic methyl-aminolevulinate (MAL) is frequently used (Metvix®, 
Galderma).22 Szeimies et al. describe a lesion response of 92.2% (118/128) 3 months 
after treatment of sBCC with MAL-PDT. Among these cleared lesions 9.3% recurred at 12 
months follow-up.43 Basset-Seguin et al. reported a recurrence rate of 22% after 5 years 
follow-up and more recently Arits et al. describe a recurrence rate of 27.2% after 1 year 
follow-up.44,45 Differences in the reported outcomes can be explained because of the use 
of different illumination schedules, the number of illuminations and whether patients 
were re-illuminated in case of treatment failure. Up to date there is very limited literature 
describing a 2-fold illumination schedule with MAL-PDT. There is only one mouse study, 
4.1  |   Effi
cacy of 5-am
inolevulinic acid PD
T for the treatm
ent of superficial basal cell carcinom
a: a retrospective study 
113
in which the twofold illumination does not increase efficacy.46 As there is very limited 
literature on the described 2-fold ALA-PDT protocol, it might be of additional interest to 
compare this protocol with illuminations using for example routine MAL-PDT in future 
prospective research.
Important limitations of our study are the retrospective nature, the lack of a control group 
and analysis of single center data. Furthermore, the ALA cream was produced in our 
hospital pharmacy, which might be difficult to reproduce. In our center PDT is a rou-
tine therapy for sBCC. Patients were able to choose their preferred treatment (topical 
imiquimod cream, 5-fluorouracil cream, surgical excision or PDT) after explanation of the 
treatments by their physician. This may have caused selection bias.
In conclusion, our results imply that ALA-PDT using a twofold illumination protocol for sBCC 
has acceptable long-term efficacy rates. It may be less effective in the head and neck area 
and in tumors with a diameter larger than 10 mm.
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Abstract
Background 
Basal cell carcinoma (BCC) is the most common type of skin cancer with growing incidence 
rates. Photodynamic therapy (PDT) is a frequently used treatment, especially for superficial 
BCC (sBCC). Two topical photosensitizing agents are currently used to treat sBCC: 5-ami-
nolevulinic acid (ALA) and its methyl-ester (MAL). Previous research showed a high efficacy 
of ALA-PDT using a 2-fold fractionated illumination scheme in which two light fractions of 
20 and 80 J/cm2 are delivered, four and six hours after ALA application. 
Objectives
To evaluate whether this 2-fold ALA-PDT is superior to conventional MAL-PDT for sBCC. 
Methods
We performed a single blind, randomized multi-center trial in the Netherlands. 
Results
162 patients were randomized to either conventional MAL-PDT or 2-fold ALA-PDT. After 
12 months a total of 6 treatment failures occurred after ALA-PDT and 13 after MAL-PDT. 
The 12 months cumulative probability of remaining free from treatment failure was 92.3% 
(95% CI [83.7-96.5]) and 83.4 (95% CI [73.1-90.0]), respectively (p=0.091). 
Conclusions
The 2-fold ALA-PDT scheme resulted in fewer recurrences, although the difference 
between both treatment groups was not statistically significant. On the contrary, it resulted 
in higher pain scores and more post-treatment side-effects compared to MAL-PDT.
Clinical trial registry number: NCT01491711
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Introduction
Basal cell carcinoma (BCC) is the most common type of skin cancer with growing incidence 
rates.1 BCC can be categorized into three histological subtypes: superficial, nodular, and 
infiltrative.2 Most BCCs are treated with surgical excision. However, one third of BCCs are 
superficial and do not necessarily require excision. Topical treatments such as photody-
namic therapy (PDT), 5-fluorouracil cream and imiquimod cream are frequently used. A 
recent randomized comparative study showed an efficacy of these treatments varying 
from 72.8%-83.4%.3 
Compared to topical ointments, the advantage of PDT is the short duration and a good 
cosmetic outcome.4,5 Topical porphyrin precursors are applied to the skin and converted 
into protoporphyrin IX (PpIX). When exposed to oxygen and light in the appropriate wave 
length, singlet oxygen is formed and the tumor cells are destroyed.6-8 Two photosensitizers 
are currently used to treat sBCC: 5-aminolaevulinic acid (ALA) and methyl-aminolaevuli-
nate (MAL). A systematic review by Peng et al. showed a weighted clearance rate (CR) of 
87%.9 Overall CR one year post-treatment of 72.8-84.0% are observed for MAL-PDT.3,10,11 
There is no randomized controlled trial that directly compares treatment with ALA- and 
MAL-PDT for sBCC. 
De Haas et al. investigated whether a 2-fold illumination scheme on one day after a single 
ALA application could lead to a better efficacy. One year post-treatment, a CR of 97% was 
observed after treatment with this 2-fold ALA-PDT scheme.12 In a recent retrospective 
study, a CR of 90.2% after one year follow up was found.13  
The current study aims to assess whether 2-fold ALA-PDT is more effective than MAL-PDT 
for the treatment of sBCC. 
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Materials and methods
This single blinded randomized controlled trial was performed at the outpatient depart-
ments of two Dutch university hospitals (Maastricht University Medical Center (MUMC+) 
and Erasmus Medical Center Rotterdam (EMC)) and one regional hospital (VieCuri Medical 
Center Venlo/Venray (VCMC)). 
Patients
Patients aged 18 years and older, with a primary histologically confirmed sBCC were eligible 
for inclusion. In case a patient had more than one eligible sBCC, the tumor with the larg-
est diameter was included. Exclusion criteria were the use of immunosuppressive drugs, 
presence of a genetic skin cancer disorder, prior treatment at the same site, porphyria, 
pregnancy and breastfeeding and a known allergy to one of the ointment components. 
sBCC localized in the high-risk area of the face (H-zone), the hairy scalp and convex or 
concave areas such as the ears or fingers, were also excluded because of a known inferior 
efficacy of PDT in these areas. All patients received written information about the study and 
gave their informed consent prior to treatment. The study was approved by the medical 
ethical board of the Erasmus Medical Center Rotterdam and was performed in accordance 
with the Declaration of Helsinki. The trial was registered at clinicaltrials.gov (NCT01491711). 
Randomization and masking
Patients were randomized using computer-generated lists, using permuted blocks of 
6. Research physicians did not have access to the randomization lists. These lists were 
saved in a closed closet at the department of dermatology of the Maastricht University 
Medical Center. Only one secretary had access to this list. All study visits (baseline, 3 and 
12 months post-treatment) were performed by two investigators blinded for treatment 
allocation. Patients could not be blinded for treatment allocation because of the different 
illumination schemes. 
Procedures
A baseline visit was planned in which tumor and patient characteristics were recorded 
and patients were included in the study. 
The 5-ALA 20% ointment (Tiofarma B.V., Oud-Beijerland, the Netherlands) was applied 
to the tumor surface 1-2 mm thick with a margin of 5 mm healthy surrounding skin. The 
treatment area was then covered with an occlusive dressing (Tegaderm ®, 3M, Leiden, 
the Netherlands), a gauze and tinfoil to prevent illumination by UV light. After 4 hours, the 
tumor was illuminated with a light emitting diode (LED) light source (Aktilite, Galderma 
SA, Lausanne, Switzerland, or Omnilux, Waldmann phototherapeutics, London, United 
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Kingdom). These light sources produce red light with an optimum wavelength of ~630 
nm +/- 5 nm and a fluence of 20J/cm2 during 4 minutes. Subsequently the treatment area 
was covered again in the same manner for 2 hours, whereupon a second illumination 
with 80 J/cm2 during 18 minutes took place. Both illuminations took place at an irradiance 
of 50 mW/cm2.
Patients who received MAL-PDT were treated with Metvix® ointment (Galderma SA, Penn 
pharmaceutical services, Gwent, United Kingdom) that was applied to the tumor in the 
exact same way as 5-ALA ointment. The tumor was covered with an occlusive dressing 
and after 3 hours illuminated with either Aktilite or Omnilux, 37 J/cm2, 75 mW/cm2, during 
7 minutes. This regimen was repeated one week later. 
All treatments were performed by qualified and trained nurses. All study medication was 
prepared and labelled according to good manufacturing practice (GMP) guidelines. 
Outcomes
Primary outcome was the probability of treatment success at 12 months follow-up. In 
case of clinical suspicion of residual tumor at 3 months or recurrent tumor at 12 months, 
a biopsy was taken for histological examination. If tumor was found this was considered 
a treatment failure. 
Secondary outcomes were aesthetic outcome and adverse events. Aesthetic outcome was 
measured on a four-point scale (poor, fair, good or excellent) and scored independently by 
two investigators blinded to treatment allocation. Treatment failures were scored as poor 
cosmetic outcome, because according to the protocol these tumors had to be excised. 
Excision results in a scar which generally compares unfavorably with cosmetic outcome 
after non-invasive treatment.  
Patients completed diaries from which data on adverse events were extracted. Patients 
were asked to score adverse events on a four-point scale (absent, mild, moderate or 
severe), one week after both illuminations. Pain and burning sensation were scored using 
a numerical rating scale (score 0-10), directly after and one week post both illuminations. 
The maximum pain scores of both illuminations were assessed. Occurrences of serious 
adverse events (SAEs) or suspected unexpected serious adverse reactions (SUSARs) were 
registered. 
Statistical analysis
The aim was to assess whether the 2-fold 5-ALA illumination protocol is superior to con-
ventional MAL-PDT. It was considered feasible to include 73 patients per group. This 
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sample size allows detection of clinically relevant difference of 15% between groups with 
a power of 80% (two-sided alpha=5%). Taking into account a possible drop-out of 10%, 
162 patients were included. 
Kaplan Meier survival analysis was performed to estimate the cumulative probability of 
recurrence free survival at 12 months follow-up. Hazard ratios (HR) for treatment failure 
with 95% confidence intervals were calculated with Cox proportional hazard models. If 
necessary, multivariate Cox regression analysis was used to adjust for imbalances in base-
line characteristics between randomized groups.  
For secondary outcomes, between group differences in proportions were tested using 
the Chi square test and mean-values of continuous variables were compared using the 
Students t-test for independent samples or the non-parametric Mann-Whitney-U test. 
P-values ≤ 0.05 were considered statistically significant. All data were analyzed using SPSS 
version 23.0 (SPSS, Chicago, IL, U.S.A), openepi.com or Stata version 14.0 (Stata Corp, 
College Station, TX, U.S.A).
Results
Between September 2013 and May 2015, 201 patients were recruited and assessed for 
eligibility. Thirty-nine patients refused participation for personal reasons or because they 
had a strong preference for a treatment other than PDT. A total of 162 patients were 
enrolled in the study (62 MUMC+, 60 EMC, 40 VCMC), of which 80 patients were allocated to 
MAL-PDT and 82 to 2-fold ALA-PDT. After randomization, some patients preferred another 
treatment than the allocated treatment. In the MAL-PDT group three patients preferred 
2-fold ALA-PDT, two patients 5-fluorouracil ointment and one patient surgical excision. 
In the 2-fold ALA-PDT group one patient was treated with MAL-PDT and one with topical 
5-fluorouracil. For these patients, data on the primary endpoint were available and they 
were included in the intention-to-treat analysis. Figure 1 demonstrates the trial profile. 
Table 1 shows the distribution of baseline characteristics in the randomized groups. There 
were small imbalances with respect to study center and tumor location (Table 1).
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Figure 1. Flow chart.
ALA = aminolevulinic acid. MAL = methylaminolevulinate. PDT = photodynamic therapy. 5-FU = 5-fluorouracil 
ointment. SE = surgical excision.
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Table 1. Distribution of baseline characteristics. 
MAL-PDT (n=80) 2-fold ALA-PDT (n=82)
Mean Age, years (range) 63.6 (28-83) 65.9 (38-85)
Sex, n (%)
     Male
     Female
35 (44%)
45 (56%)
40 (49%)
42 (51%)
Study center, n (%)
     MUMC+
     EMC
     VCMC
27 (34%)
34 (43%)
19 (24%)
35 (43%)
26 (32%)
21 (26%)
Tumor location, n (%)
     Head/neck
     Trunk
     Upper extremities
     Lower extremities
1 (1.3%)
58 (73%)
7 (8.8%)
14 (18%)
7 (8.5%)
45 (55%)
16 (20%)
14 (17%)
Mean tumor size in mm ± SD 11.2 ± 7.1 10.8 ± 5.3
ALA: aminolevulinic acid. MAL: methyl-aminolevulinate. PDT: photodynamic therapy.
MUMC: Maastricht university Medical Center; EMC: Erasmus Medical Center; VCMC: VieCuri Medical Center. 
Residual tumor after 3 months was seen in 4 patients treated with MAL-PDT and in 3 
patients after ALA-PDT treatment. At 12 months follow-up another 9 recurrences had 
occurred following MAL-PDT and 3 following ALA-PDT resulting in a total of 13 treatment 
failures after MAL-PDT and 6 after ALA-PDT. 
At 3 months the cumulative probability of treatment success was 96.2% (95% CI [88.7-
98.8]) for 2-fold ALA-PDT and 94.9% (95% CI [87.0-98.1]) for MAL-PDT. At 12 months, 
the cumulative probability was 92.3% (95% CI [83.7-96.5]) and 83.4 (95% CI [73.1-90.0]), 
respectively (p=0.091) (Table 2). Univariate Cox regression analysis resulted in a crude 
hazard ratio (HR) for treatment failure of 2.17 (95% CI [0.82-5.70]), indicating a higher risk 
of treatment failure after MAL-PDT. Multivariate Cox regression analysis was performed to 
adjust for the observed small imbalances in baseline characteristics between randomized 
groups. The adjusted HR from a model including treatment, study center, age, sex, tumor 
location and tumor size as independent variables was 2.35 (95% CI [0.84-6.53]). 
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Table 2: Estimated initial and sustained clearance rate according to intention-to-treat 
analysis.
Proportion of patients 
without treatment 
failure after 3 months
Proportion of patients 
without treatment failure 
within 3-12 months
Cumulative probability of 
remaining free from treatment 
failure at 12 months* 
[95% confidence interval]
ALA-PDT 76/79 (96.2%) 72/75 (96.0%) 92.3% [83.7-96.5]
MAL-PDT 75/79 (94.9%) 65/74 (87.8%) 83.4% [73.1-90.0]
Data are n/N (%). Log-rank test: p = 0.091. 
* product of initial and sustained clearance rate. 
ALA = aminolevulinic acid. MAL = methylaminolevulinate. PDT = photodynamic therapy. 
Additionally, a per protocol analysis was performed. Patients were analyzed according to 
the treatment they actually received and 4 patients who were treated by topical 5-fluoro-
uracil ointment (3) or surgical excision (1) were excluded from this analysis. The cumulative 
probability of treatment success at 12 months was 91.9 (95% CI [82.9-96.3]) for ALA-PDT 
and 83.4 (95% CI [73.1-90.0]) for MAL-PDT, p = 0.110. Crude and adjusted HR for treat-
ment failure were 2.15 (95% CI [0.81 – 5.65]) and 2.21 (95% CI [0.82-6.04]), respectively.
Adverse events
Table 3 presents the mean scores for pain and burning sensation after each illumination 
for both treatments. After the second illumination, mean pain scores were significantly 
higher in the 2-fold ALA-PDT group compared to patients treated with MAL-PDT, with mean 
pain scores 3.36 ± 2.57 and 2.48 ± 2.57, respectively (p = 0.039). None of the patients dis-
continued treatment because of pain. Overall, patients who received ALA-PDT more often 
reported side-effects. Reported incidence of erythema, wounds/erosions and vesicles was 
significantly higher after ALA-PDT compared to MAL-PDT (Table 3). Furthermore, 16.4% 
in the ALA-PDT versus 5.8% in the MAL-PDT group reported the use of pain medication 
post-treatment. 
Data on cosmetic outcome were available for 73 patients treated with ALA-PDT and 72 
patients with MAL-PDT. Good to excellent cosmetic outcome was reported in 79.5% 
(58/73) of ALA-PDT patients and 66.7% (48/72) of MAL-PDT patients (p = 0.084). No seri-
ous unexpected adverse reactions were reported in both groups. During the study, four 
serious adverse events occurred (3 hospitalizations due to transient ischemic attack, che-
motherapy for lung carcinoma and dizziness, and 1 patient died due to cancer), which 
were un-related to the study treatment.
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Table 3: Adverse events
MAL-PDT 2-fold ALA-PDT p-value 
Pain score, mean NRS ± SD
     During first PDT session
     During second PDT session
2.25 ± 2.54
2.48 ± 2.57
1.88 ± 2.36       
3.36 ± 2.57
0.369
0.039*
Burning sensation score, mean NRS ± SD
      During first PDT session
      During second PDT session
3.12 +/- 2.72
2.94 +/- 2.72
3.41 +/- 2.37     
4.49 +/- 2.06     
0.457
0.001*
Erythema, n/N (%)
     absent/ mild
     moderate/ severe 
     not available 
37/73 (50.7%)
28/73 (38.4%)
8/73 (11%)
13/80 (16.3%)
59/80 (73.8%)
8/80 (10%)
<0.001*
Swelling, n/N (%)
     absent/ mild
     moderate/ severe
     not available
61/73 (83.6%)
5/73 (6.8%)
7/73 (9.6%)
63/80 (78.8%)
9/80 (11.3%)
8/80 (10%)
0.406
Wounds, n/N (%)
     absent/ mild
     moderate/ severe
     not available
60/73 (82.2%)
4/73 (5.5%)
9/73 (12.3%)
56/80 (70%)
16/80 (20%)
8/80 (10%)
0.014*
Crusts, n/N (%)
     absent/ mild
     moderate/ severe
     not available
60/73 (82.2%)
6/73 (8.2%)
7/73 (9.6%)
57/80 (71.3%)
15 (18.8%)
8/80 (10%)
0.062
Vesicles, n/N (%)
     absent/ mild
     moderate/ severe
     not available
61/73 (83.6%)
5/73 (6.8%)
7/73 (9.6%)
54/80 (67.5%)
18/80 (22.5%)
8/80 (10%)
0.011*
Scaling, n/N (%)
     absent/ mild
     moderate/ severe
     not available
59/73 (80.8%)
7/73 (9.6%)
7/73 (9.6%)
57/80 (71.3%)
14/80 (17.5%)
9/80 (11.3%)
0.160
Pruritus, n/N (%)
     absent/ mild
     moderate/ severe
     not available
53/73 (72.6%)
13/73 (17.8%)
7/73 (9.6%)
56/80 (70%)
16/80 (20%)
8/80 (10%)
0.835
NRS: numeric rating scale (0-10), SD: standard deviation 
Mean NRS scores were tested for statistical significance using the student’s t-test. Differences in categorical data 
were tested for statistical significance using the Chi-square test. 
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Discussion
Our data suggest that patients treated with the 2-fold ALA-PDT scheme have a higher 
cumulative probability of remaining free from treatment failure one year post-treatment, 
compared to patients treated with conventional MAL-PDT (92.3% versus 83.4%), although 
the difference is not statistically significant. In addition, patients treated with ALA-PDT 
experienced more pain and local side-effects. 
This is the first randomized controlled trial comparing MAL-PDT with a 2-fold ALA-PDT 
regimen. World-wide many PDT studies are performed investigating both MAL and ALA 
photosensitizers. In Europe, MAL is approved as Metvix® (Galderma SA, Penn pharmaceu-
tical services, Gwent, United Kingdom) for treatment of BCC, actinic keratosis and Bowens 
disease.14,15 In the U.S.A Metvix® is only approved for the treatment of AK.16 MAL is more 
lipophilic and therefore has the theoretical benefit of a higher and faster intracellular 
absorption compared to ALA. MAL also has a higher selectivity for tumor cells leading to 
fewer side effects in normal healthy tissue.17-20 
A systematic review studying the efficacy of several non-invasive treatments for sBCC 
showed a pooled estimate of tumor-free survival at one year of 76.2% for PDT, including 
both ALA and MAL-PDT.21 The majority of studies assessed efficacy of ALA-PDT after a 
single unfractionated illumination. A higher tumor free survival was observed when PDT 
treatment was repeated (84%).  A more recent study reported a one year CR of 72.8% 
after conventional MAL-PDT.3
To optimize efficacy, de Haas et al. studied a fractionated 2-fold ALA-PDT protocol for 
sBCC with a first dose of 20 J/cm2 followed by a dark interval and a second dose of 80 J/
cm2. They performed a prospective comparative study in which a CR of 97% after 2-fold 
ALA-PDT versus 89% after a single illumination was reported one year post-treatment.12 
The superiority of the 2-fold ALA-PDT regimen was confirmed by de Vijlder et al. who 
described a CR of 88% after 2-fold ALA-PDT 5 years post-treatment.22 
The fractionated illumination protocol has been studied pre-clinically in a variety of 
models.22,23 It is suggested that by applying two consecutive illuminations, there might be 
an additional utilization of PpIX due to re-oxygenation during the dark interval.22 Further-
more, there might be an enhanced local immune response when using light fractionation.22 
Previous PDT literature describes a relation between vascular response, oxygen supply 
and an effective PDT response.24-27 Middelburg et al. reported a higher accumulation of 
PpIX in endothelial vessel walls after ALA application, compared to MAL. After illumination, 
more endothelial damage was observed.28 Despite these described hypotheses, the exact 
explanation for an enhanced efficacy is not yet fully elucidated. 
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The CR of 92.3% for 2-fold ALA PDT as observed in this trial is lower compared to the 
previous results from de Haas et al. whereas a higher CR after MAL-PDT was observed 
compared to the study by Arits et al, who reported a CR of 72.8% at 1 year after treatment.3 
Differences between study populations might be responsible. For instance, in our sample 
only one patient in the MAL-PDT group had a BCC in the head and neck area, an area that 
is known to be associated with higher risk of treatment failure, whereas in the trial of Arits 
et al. 12% of the patients had a BCC in this area.3,29 Direct comparison of treatments within 
randomized trials is necessary to validate conclusions on comparative efficacy. 
Additionally, we found significantly higher pain scores after 2-fold ALA-PDT compared to 
MAL-PDT. Erythema, wounds and vesicles occurred significantly more frequently in the 
2-fold ALA-PDT group. The reported stronger effect on vascular endothelium and local 
immune response might be an explanation for these observations. 
Previous literature demonstrated a favorable cosmetic outcome after PDT compared to 
surgery for BCC.30,31 Despite of more local skin reactions, we observed a trend towards a 
better cosmetic outcome after 2-fold ALA-PDT compared to MAL-PDT. MAL-PDT results 
are comparable with Arits et al., who found good-excellent cosmetic outcome in 62% of 
patients treated with MAL-PDT.3 
The fact that PDT is an in-clinic treatment could be an advantage over other topical 
home-based treatments for specific patient categories such as the elderly. An additional 
advantage of the 2-fold ALA-PDT versus topical ointments or conventional MAL-PDT is 
that it can be performed within one day. Furthermore, costs of the PDT treatment are 
supposed to be less because the ointment needs to be applied only once and in The 
Netherlands ALA ointment is less expensive than MAL (Metvix®, Galderma) ointment.
A limitation of this trial is that the sample size enabled detection of an absolute difference 
in proportion with treatment failure of 15% or larger with a power of 80% (alpha=5%). The 
expected difference of 15% was based on prior studies.3,12 However, we observed a differ-
ence between ALA-PDT and MAL-PDT of 8.9% in favor of ALA-PDT and the power to detect 
this difference with 95% confidence was too low. Long-term follow-up and larger patient 
cohorts might be needed to detect a statistically significant difference between both treat-
ments. An additional limitation is that post-treatment biopsies were not performed to 
confirm a lack of tumor and it is possible that clinical and dermoscopic examination missed 
some recurrences that had not yet surfaced. However, potential underreporting of recur-
rences is unlikely to affect the comparison of treatment success between both groups. 
It should be kept in mind that this study does not only compare two different drugs (ALA 
and MAL) but additionally the regimen is variable: the treatment with ALA was fractionated 
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on one day whereas MAL protocol consisted of two illuminations with one week interval. 
For future studies it would be interesting to compare the 2-fold fractionated ALA-PDT with 
a comparable fractionated MAL-PDT regimen. Although 2-fold MAL-PDT has not yet been 
studied in humans, previous studies on mouse-models did not show a favorable response 
of fractionation in MAL-PDT.32,33
In conclusion, our results suggest a trend towards a better efficacy of 2-fold-ALA-PDT 
compared to conventional MAL-PDT for the treatment of sBCC, although the difference 
is not statistically significant. The 2-fold ALA-PDT regimen however entails a higher risk of 
pain and side-effects. 
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“Darkness cannot drive out darkness: only light can do that. 
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Introduction
Photodynamic therapy (PDT) is a non-invasive treatment for several (pre)malignant super-
ficial skin cancers, such as superficial basal cell carcinoma (sBCC), Bowen’s disease (BD) 
and actinic keratosis (AK).1,2 PDT is traditionally known as an in-clinic treatment that can 
be time-consuming for both patients and healthcare personnel. Prior studies have also 
shown that conventional PDT (cPDT) can be painful.3 In order to optimize comfort during 
treatment, new photosensitizing agents and light sources have been studied over the 
past decades. 
Moseley et al. reported on the use of a portable low-irradiance illumination source for 
sBCC.4 This ambulatory PDT (aPDT) device delivers a standard light dose at low irradiance 
(7 mW/cm2) over a prolonged period of time, compared to other devices such as the Aktilite 
(80-90 mW/cm2, Galderma SA, Lausanne, Switzerland).5 It is considered a patient friendly, 
out of clinic treatment with lower pain scores compared to regular PDT.4-6 
In this study we retrospectively evaluated the risk of recurrence in patients treated with 
aPDT for primary sBCC and the effect of tumor size on recurrence. 
Materials and methods
Medical files of patients treated with aPDT between February 1st 2012 and May 31st 2013 
in the Catharina hospital, the Netherlands, were retrospectively reviewed. Eligible for 
this study, were patients with a histologically confirmed primary sBCC with a maximum 
diameter of 2 centimeters (due to size limitation of the portable PDT device). Excluded 
were patients with genetic disorders causing skin cancer and patients using immunosup-
pressive medication. The primary outcome measure was 1-year probability of remaining 
tumor-free. Treatment failure was defined as the presence of residual or recurrent tumor 
during follow-up visits. Follow-up visits were scheduled according to the local hospital 
protocol 3 and 12 months post-treatment. Secondary outcome measures were cumulative 
probability of recurrence free survival at 6 and 18 months and incidence of adverse events.
Treatment procedure
In case of slight hyperkeratosis, lesions were prepared by curettage using a wooden spat-
ula to remove scales and crusts, to increase penetration of the active agent. Consecutively 
methyl-aminolevulinate (Metvix, Galderma SA, Penn pharmaceutical services, Gwent, UK) 
was applied to the tumor itself and a 5 mm margin of surrounding normal tissue. A trans-
parent occlusive bandage (Tegaderm®, 3M Healthcare, Minnesota, USA), was applied, 
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after which the portable PDT device (Ambulight®, Ambicare Health, Livingston, Scotland) 
was attached. The device remained switched off for 3 hours. After that, it switched on 
automatically and remained switched on for another 3 hours, hereby delivering a total 
light dose of 75 J/cm2, with 7 mW/cm2 irradiance. 
Statistical analysis
The distribution of baseline characteristics was described by absolute numbers and per-
centages for categorical variables and mean ± standard deviation for age. Kaplan Meier 
survival analyses were used to assess the cumulative probability of recurrence free survival 
with 95% confidence intervals at 6, 12 and 18 months. Differences in recurrence free 
survival between groups were tested for significance using the log-rank test. Follow-up 
ended at the date of a treatment failure or the date of the last follow-up visit. A two-sided 
p-value ≤0.05 was considered to indicate statistical significance. Analyses were performed 
using SPSS version 23.0 (SPSS, Chicago, IL, U.S.A) and STATA version 14.0 (STATA Corp, 
College Station, TX, U.S.A).
Results
During the study period 125 patients with 143 sBCC were treated with aPDT. The first 
diagnosed tumor per patient was included for analysis. In case a patient was treated for 
two or more primary sBCC on the same day, the largest tumor was chosen for analysis. 
A total of 104 patients had a histologically confirmed primary sBCC. Three patients were 
lost to follow-up directly post-treatment, because they preferred follow-up elsewhere. 
Thus, 101 patients remained for analysis. Baseline characteristics are shown in table 1. 
Median follow-up time was 13 months (range 2-23) with 59.4% of patients having com-
pleted a follow-up time of at least 12 months and 27% more than 18 months. In 11 patients 
treatment failure was observed based on clinical observation. Eight of the clinically suspect 
recurrences were confirmed by histopathological examination, three tumors were retreated 
without histological confirmation. Eleven recurrences were included in the analysis. 
At 3 months there were no patients with residual tumor. At 6, 12 and 18 months the 
cumulative probability of recurrence free survival was 93.6% (95% CI [86.3-97.1]), 89.9% 
(95% CI = [81.5-94.7]) and 87.6% (95% CI [77.4-93.3]) .For 74 patients data on tumor size 
was available. These patients were categorized according to tumor size: ≤ 5 mm, 6-10 mm 
and > 10 mm. The 1-year probability of recurrence free survival was 100% for the ≤ 5 mm 
size group and 92% (95% CI [78.5-97.6]) and 72.9 (95% CI [42.6-89.0]) for the 6-10 mm 
and > 10 mm groups respectively, p-value = 0.014 (Figure 1 and Table 2).  
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Table 1. Baseline characteristics. 
Age (years), mean ± SD 63.6±11.7
Sex, n (%)
     Male 
     Female
53 (52.5)
48 (47.5)
Tumor size, n (%)
    <5 mm
    5-10 mm 
    10-20 mm
    Unknown  
10 (9.9)
48 (47.5)
16 (15.8)
27 (26.7)
Lesion location, n (%)
     Head / neck
     Upper extremity
     Lower extremity
     Back 
     Chest/abdomen
1 (1.0)
22 (21.8)
13 (12.9)
41 (40.6)
24 (23.8)
SD: standard deviation 
Figure 1. Kaplan Meier survival curve according to tumor size. 
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Table 2. 1-year survival data for recurrence. 
Tumor size 1 year risk of recurrence free survival (95% CI), % p-value 
≤ 5 mm 100
6-10 mm 92.6 (78.5-97.6)
> 10 72.9 (42.6-89.0) 0.014*
CI, confidence interval; *p-value <0.05
Adverse events were reported in two patients: one patient reported blistering and ero-
sions post-treatment and the other patient had a bacterial skin infection, treated with 
topical antibacterial ointment. 
Discussion
The current study suggests that aPDT seems to be an effective treatment for primary 
sBCC with clearance rates of 89.9% at 12 months follow-up. It is most effective in sBCC 
smaller than 10 mm. 
The probability of recurrence free survival following aPDT compares favorably to results 
reported by studies on cPDT. Roozeboom et al. found a 1-year cumulative probability of 
84% (95% CI [78-90]) based on pooled estimates of recurrence free survival in a systematic 
review on cPDT treatment of sBCC.7 In a recent prospective randomized controlled trial 
probability of recurrence free survival of 72.8% (95% CI [66.8-79.4]) was reported at 12 
months following MAL-PDT.8 A possible explanation for better  results of aPDT might be 
the different irradiance in aPDT. The aPDT device emits red light at low irradiance over 
a longer period of time. It is hypothesized that this low irradiance is more cytotoxic and 
has a greater photobleaching efficiency and therefore could lead to a higher efficacy.9,10 
However, the lack of a control group in this study prohibits direct comparison with cPDT.
An interesting finding in the current study is that aPDT is especially effective in tumors 
<10 mm. The decrease in treatment success in larger tumors has already been reported 
by Atilli et al. in a small open pilot study with aPDT. They observed that lesions larger 
than 1.5 centimeter were more likely to show recurrence.6 One could argue that smaller 
sBCC, in general, respond better to treatment compared to larger ones. However, PDT 
literature is not consistent regarding the association between tumor size and effective-
ness of PDT .11-15
 
An important limitation of this study is the retrospective nature of the study. Reports 
were often brief and post-treatment photography was usually not conducted. For this 
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reason, recurrences may have been misclassified and adverse events may have been 
underreported. 
Currently, aPDT is not widely implemented in daily practice in Dutch hospitals. A limita-
tion of the device is the inability to treat tumors located on convex or concave areas (e.g. 
nose, fingers) or tumors > 2 centimeters. Since there are viable and more cost-effective 
alternative therapeutic options such as imiquimod or 5-fluourouracil, the position of aPDT 
has to be established. aPDT could be a preferred mode of PDT for the working popula-
tion, for whom in-clinic treatment might not be preferable and for patients who are not 
able or willing to apply a cream. Another advantage could be the good tolerance during 
illumination, in contrast to cPDT in which a burning sensation is more often reported.5,6 
Thus far, there is insufficient evidence to implement aPDT on a wide scale and comparison 
to other existing effective treatments in a randomized controlled setting is warranted. 
142
References
1. Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 
5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clinics in dermatology. 
2013;31(6):792-798.
2. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic 
therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen’s disease, 
basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV. 
2013;27(5):536-544.
3. Arits AH, van de Weert MM, Nelemans PJ, Kelleners-Smeets NW. Pain during topical photodynamic 
therapy: uncomfortable and unpredictable. Journal of the European Academy of Dermatology and 
Venereology : JEADV. 2010;24(12):1452-1457.
4. Moseley H, Allen JW, Ibbotson S, et al. Ambulatory photodynamic therapy: a new concept in 
delivering photodynamic therapy. The British journal of dermatology. 2006;154(4):747-750.
5. Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic 
light-emitting diodes for the treatment of non-melanoma skin cancer: an open study. Photoder-
matology, photoimmunology & photomedicine. 2012;28(5):235-239.
6. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory photodynamic therapy 
using a wearable low-irradiance organic light-emitting diode light source in the treatment of 
nonmelanoma skin cancer. The British journal of dermatology. 2009;161(1):170-173.
7. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after 
treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of 
randomized and nonrandomized trials. The British journal of dermatology. 2012;167(4):733-756.
8. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus 
topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, 
randomised controlled trial. Lancet Oncol. 2013;14(7):647-654.
9. Cottrell WJ, Paquette AD, Keymel KR, Foster TH, Oseroff AR. Irradiance-dependent photo-
bleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell 
carcinomas. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2008;14(14):4475-4483.
10. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to 
photodynamic therapy. Photochemistry and photobiology. 1998;67(4):462-466.
11. Roozeboom MH, Nelemans PJ, Mosterd K, Steijlen PM, Arits AH, Kelleners-Smeets NW. Photody-
namic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup 
analysis within a noninferiority randomized controlled trial. The British journal of dermatology. 
2015;172(3):739-745.
12. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical 
and pathological determinants of response. Journal of the European Academy of Dermatology and 
Venereology : JEADV. 2011;25(8):896-901.
13. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients 
with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional 
treatment. The British journal of dermatology. 2003;149(6):1242-1249.
14. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol. 
1998;134(2):207-214.
15. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate 
photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 
12-month follow-up. Journal of the European Academy of Dermatology and Venereology : JEADV. 
2008;22(11):1302-1311.

EM
BA
RG
OE
D
This chapter is embargoed at request

Chapter 6 
Summary
Samenvatting
162
Sum
m
ary
163
Summary
Over the past years there has been a rise in the incidence of skin cancer. The work 
presented in this thesis focused on non-invasive treatment modalities for both actinic 
keratosis (AK) and superficial basal cell carcinoma (sBCC): several retrospective data stud-
ies and prospective randomized trials were performed. 
Chapter 1 gives a general introduction to both AK and sBCC. Chapter 2 discusses treat-
ment options for AK. In chapter 2.1 an overview of the available literature is presented, in 
which the most frequently used therapies are summarized. Photodynamic therapy (PDT), 
for example, is a well-established treatment for several keratinocyte carcinoma (KC) and 
its precursors. It is known that AK patients experience pain during PDT illumination. This 
frequently leads to discontinuation of treatment or refusal of future follow-up treatments. 
In a split face study (chapter 2.2), we investigated whether the use of a pulsed dye laser 
(PDL) device as illumination source during PDT, was associated with lower pain scores 
compared to conventional LED-PDT. We found that patients reported lower pain scores 
and side effects after PDL illumination. The PDL device is however expensive and not 
available in all clinics, which makes it only an alternative treatment option in case in-clinic 
treatment is desired and pain is a limiting factor. 
 
In the literature review of chapter 2.1, we found that studies were methodologically het-
erogeneous and there was a need for more head-to-head trials comparing the most 
frequently used treatments. It was not possible to draw a solid conclusion on what treat-
ment is the most effective for a continuous area with multiple AKs (so called field-AK). This 
initiated a large randomized controlled study in chapter 2.3, that compared the effective-
ness of topical 5-fluorouracil, imiquimod, ingenol mebutate and methylaminolevulinate 
photodynamic therapy (MAL-PDT) with one another. A total of 624 patients in 4 different 
hospitals participated. Three months follow-up data show that 5-fluorouracil cream is 
superior to the other mentioned treatments for field AK: 90.2% of patients treated with 
5-fluorouracil had ≥75% reduction in AK lesions, compared to baseline. Results for imiqui-
mod, PDT and ingenol mebutate were respectively 76.4%, 76.0% and 67.3%. In this study 
patients could only receive one re-treatment in case of <75% lesion reduction. Only 14.8% 
of the patients treated with 5-fuorouracil needed a second treatment cycle due to initial 
insufficient effectiveness, before the 3 months assessment was done. For imiquimod, MAL-
PDT and ingenol mebutate these percentages were 35.9%, 43.6% and 47.8%, respectively.
 
Various treatments are available for BCC, with surgical treatment as gold standard. As 
invasive treatment is not always the preferred treatment, especially in the case of the 
superficial BCC, many topical non-invasive treatments are used. Nowadays, cancer medi-
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cine increasingly aims to focus on molecular medicine and targeted therapies in order to 
block tumour growth more specifically. The majority of BCC contains patched 1 (PTCH1) 
mutations, which lead to an inhibition of the Hedgehog (HH) pathway. There is some evi-
dence that there might be a role for the Wingless (WNT) pathway in BCC. Dysregulation of 
the WNT pathway leads to the stacking of nuclear b-catenin enhancing tumour cell pro-
liferation. We aimed to investigate whether topical sinecatechin ointment (which consists 
among others of epigallocatechin-3-gallate), could lead to tumour proliferation arrest or 
tumour clearance. In a randomized placebo controlled study we could not find a statisti-
cally significant clinical, histological or immunochemical effect of the topical sinecatechin 
ointment on BCC (chapter 3). 
Previous studies showed that when comparing PDT with topical 5-fluorouracil and imiqui-
mod in the treatment of sBCC, PDT was less effective both at one and three and five-year 
follow-up in sBCC. It might however still be a desired treatment for a certain subcategory 
of patients. One can think of the elderly, patients who are unable to complete a self-ap-
plicable treatment etcetera). Previous studies showed a high efficacy using a fractionated 
ALA PDT scheme. We performed a retrospective study (chapter 4.1) assessing 323 primary 
sBCC treated with this fractionated 2-fold aminolevulinic acid 20% (ALA) PDT. With this 
scheme, two light fractions of 20 and 80 J/cm2 are delivered, 4 and 6 hours after 5-ALA 
application, respectively. Our results showed a cumulative probability of recurrence free 
survival of 88.8% after 12 months, 81.8% after 24 months and 77.1% after 48 months 
follow-up. In order to further assess the effectiveness in a more controlled setting and in 
order to compare it to the conventional MAL-PDT scheme, we performed a multi-centre 
randomized controlled trial in which 162 patients with primary sBCC participated (chapter 
4.2). Although the difference was not statistically significant, the 2-fold ALA-PDT scheme 
did lead to fewer recurrences at 12 months follow-up compared to MAL-PDT: 6 versus 13. 
Another advantage of this scheme above the conventional MAL scheme is that the one 
day treatment is more efficient than two illuminations one week apart, as is the case with 
the conventional MAL scheme. 
In chapter 4.3 we retrospectively assessed the effectiveness of an ambulatory PDT (aPDT) 
device to treat sBCC. Results show that aPDT is an effective treatment for primary sBCC 
with a clearance rate of 89.9% at 12 months follow-up. Limitations of the device are its 
costs and the inability of treating tumours on every location and tumours larger than 2 
centimetres. In chapter 5 results and implication for clinical practise are described and 
discussed in further detail.  
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Samenvatting
De afgelopen jaren is er een stijging gezien in de incidentie van huidkanker, zowel in 
Nederland als de rest van de wereld. Dit proefschrift richt zich op de niet-chirurgische 
behandelingen van twee veel voorkomende aandoeningen: actinische keratose (AK) en 
het oppervlakkige (superficieel) basaalcelcarcinoom (sBCC) en laat de resultaten zien van 
zes studies. 
Hoofdstuk 1 geeft een algemene introductie over beide aandoeningen. Hoofdstuk 2 richt 
zich op de behandeling van AK. Allereerst wordt in hoofdstuk 2.1 een overzicht van de lit-
eratuur gegeven waarin de meest voorkomende behandelingen op een rij gezet worden. 
Photodynamische therapie (PDT) bijvoorbeeld, is een gekende behandeling binnen de 
dermato-oncologie. Omdat pijn tijdens de PDT behandeling voor veel AK patiënten een 
beperkende factor is, hebben we in hoofdstuk 2.2 onderzocht of de pijn minder is als er 
belicht wordt met een pulsed dye laser (PDL). In een zogeheten ‘split-face’ studie hebben 
wij de conventionele PDT vergeleken met PDL gemedieerde PDT. Resultaten lieten zien 
dat patiënten minder pijn rapporteerden na PDL belichting. Het PDL apparaat is echter 
duur in de aanschaf en niet iedere kliniek beschikt over deze apparatuur. Dit maakt het 
daarom enkel een alternatieve behandeloptie als behandeling in het ziekenhuis gewenst 
is en pijn een beperkende factor is.  
Uit de literatuurstudie van hoofdstuk 2.1 bleek ook dat studies naar AK erg wisselen in 
studie-opzet, onderzochte patiënt populatie en uitkomstmaten. Het is dus op basis van 
de huidige literatuur niet mogelijk een goede conclusie te trekken over wat de meest 
effectieve behandeling is voor een gebied met meerdere AK’s (zogeheten veld-AK). Om 
die reden hebben wij een prospectieve gerandomiseerde studie opgezet waarvan de 
resultaten in hoofdstuk 2.3 worden gepresenteerd. In deze studie hebben wij de vier meest 
toegepaste behandelingen van veld-AK onderzocht: 5-fluourouracil crème, imiquimod 
crème, ingenol mebutate gel en photodynamische therapie (PDT). Een totaal van 624 
mensen, verdeeld over 4 centra namen deel. Resultaten laten zien dat na 3 maanden 
follow-up 5-fluourouracil crème de meest effectieve behandeling is, waarbij 90.2% van 
de patiënten ≥75% reductie had van het aantal AK’s ten opzichte van begin van de studie. 
Voor imiquimod, ingenol mebutate en PDT was dit significant minder met respectievelijk 
76.4%, 76.0% en 67.3%. In deze studie mochten mensen maximaal één herbehandeling 
ondergaan, alvorens de eindevaluatie plaatsvond. Deze herbehandeling werd verricht 
indien er <75% reductie was van het aantal AK‘s. Slechts 14.8% van de patiënten die 
met 5-fluorouracil crème werden behandeld, hadden een tweede behandelcyclus nodig. 
Deze percentages waren 35.9%, 43.6% en 47.8%, voor imiquimod crème, PDT en ingenol 
mebutate gel respectievelijk.
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Naast het onderzoeken van reeds bestaande therapieën, richt onderzoek binnen de 
oncologie zich steeds meer op moleculaire mechanismen van tumoren. Het exacte mech-
anisme achter het ontwikkelen van BCC’s is nog niet volledig gekend, maar we weten 
wel dat de grote meerderheid van de BCC’s ontstaan ten gevolge van een mutatie in het 
patched 1 (PTCH 1) gen, onderdeel van de hedgehog (HH) pathway. Een andere pathway, 
de Wingless (WNT) pathway, zou mogelijk ook een rol hebben bij de tumorgroei door 
toename van nucleair b-catenine eiwit en er zijn aanwijzingen dat de HH en WNT pathway 
met elkaar communiceren. Er zijn data die suggereren dat een bestanddeel van groene 
thee – epigallocatechin-3-gallate (EGCG), een in-activatie van b-catenine tot gevolg zou 
kunnen hebben. In een gerandomiseerde placebo gecontroleerde studie hebben wij bij 
42 patiënten onderzocht of Sinecatechin 10% zalf (die o.a. bestaat uit EGCG), leidde tot 
het verdwijnen van de BCC cellen. Resultaten lieten geen klinisch, histologisch of immu-
nohistochemisch effect zien van de zalf op de BCC’s (hoofdstuk 3). 
Eerdere studies naar sBCC hebben laten zien dat vergeleken met 5-fluourouracil en imiqui-
mod crème, PDT tot de meeste recidieven leidt, zowel 1, 3 en 5 jaar na behandeling. PDT 
kan echter toch een gewenste behandeloptie zijn bijvoorbeeld voor ouderen of mensen 
die niet in staat zijn een crème zelf thuis aan te brengen. 
Wij hebben daarom geprobeerd te zoeken naar andere en mogelijk betere belichtingss-
chema’s waarmee de effectiviteit van PDT verhoogd zou kunnen worden. Eerdere studies 
hebben laten zien dat de effectiviteit van PDT bij BCC’s vergroot kan worden door de belicht-
ingen te fractioneren na aanbrengen van aminolevuline zuur (ALA). In hoofdstuk 4.1 hebben 
wij een retrospectieve dossierstudie verricht en 323 primaire sBCC’s onderzocht welke met 
gefractioneerd ALA PDT behandeld zijn. Bij dit behandelschema worden op één dag twee 
belichtingen gegeven van 20 en 80 J/cm2, respectievelijk 4 en 6 uur na aanbrengen van de 
ALA-crème. Onze resultaten laten zien dat 12 maanden na de behandeling, 88.8% van de 
patiënten geen recidief tumor had. Na 24 en 48 maanden zijn deze cijfers 81.8% en 77.1%. 
Om de effectiviteit in een meer gecontroleerde setting te beoordelen en om de vergeli-
jking te maken met het veel toegepaste MAL-PDT schema, hebben wij een multi-center 
gerandomiseerde studie verricht waaraan 162 patiënten deelnamen in 3 verschillende 
centra (hoofdstuk 4.2). Ondanks dat het verschil niet statistisch significant was, leidde het 
gefractioneerde ALA-PDT schema tot minder recidieven 12 maanden na behandeling ten 
opzichte van de conventionele MAL-PDT: 6 versus 13. Een belangrijk voordeel van het 
ALA-PDT schema is dat dit op één dag uitgevoerd kan worden. Het conventionele MAL-
PDT schema wordt op twee dagen met één week tussenpauze verricht. 
 
In hoofdstuk 4.3 hebben wij de effectiviteit van een draagbaar PDT apparaat (aPDT) in een 
retrospectieve studie onderzocht. De resultaten laten zien dat aPDT een effectieve behan-
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deling is voor primaire sBCC’s waarbij 89.9% van de patiënten 12 maanden na behandeling 
nog tumorvrij is. Beperkingen van het apparaat zijn de kosten en het feit dat niet op iedere 
lokalisatie behandeld kan worden en ook tumoren groter dan 2 centimeter niet behandeld 
kunnen worden. Hoofdstuk 5 beschrijft en interpreteert de resultaten en conclusies van 
het gedane onderzoek en bediscussieerd de relevantie voor de dagelijkse praktijk.   
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Dankwoord
Het is af en daarmee bijna onwerkelijk om te mogen beginnen aan het dankwoord. Na 
jaren van onderzoek doen met alle ups en downs die daarbij komen kijken, is het dan 
zo ver. Ik kijk terug op een intensieve maar ook bijzondere tijd. Dit alles was niet gelukt 
zonder de hulp en steun van velen. Ik zou graag een aantal mensen in het bijzonder willen 
bedanken.
Op de eerste plaats de patiënten: zonder patiënten, geen onderzoek! Mijn dank is groot 
aan alle mensen die mee hebben gedaan aan de verschillende klinische studies van dit 
proefschrift. Het vergt vertrouwen, durf en tijd om mee te doen aan onderzoek.  
Beste professor Steijlen. Bedankt voor het vertrouwen dat u in mij stelde toen ik in 2013 
bij u met de opleiding tot dermatoloog mocht beginnen. Ik heb indertijd ook de kans 
gekregen om door te gaan met onderzoek dat ik in het Catharina ziekenhuis gestart was. 
Bedankt dat u zo open was en mij de kans hebt gegeven om dit promotie-onderzoek naast 
mijn opleiding te kunnen doen. Ik waardeer dat bij u veel bespreekbaar is, u de sterke 
punten van uw AIOS ziet en hiermee mensen ook motiveert. 
Beste dr. Kelleners-Smeets, lieve Nicole. Ik weet nog goed dat dit alles begon toen ik startte 
met mijn opleiding. Ik kon met jou sparren over de laser-PDT studie uit het Catharina 
ziekenhuis en mijn wens om verder onderzoek te doen in het MUMC+. We kwamen tot 
een aantal ideeën, en zo geschiedde. Je bent een motivator, een duizendpoot en door je 
praktische kijk op dingen kunnen moeilijke knopen, ogenschijnlijk makkelijk doorgehakt 
worden. 
Beste dr. Mosterd, lieve Klara. Ons eerste gezamenlijke project was de AKTI. Ik kan me de 
vele meetings nog goed voor de geest halen. En hoe groot de blijdschap was bij het bin-
nenhalen van de ZonMw subsidie. En zie nu wat een geweldig project het is geworden! Ik 
ben dankbaar voor jouw kritische blik. Ik moest even wennen aan je directheid, maar juist 
hierdoor ben je in staat helder een probleem te schetsen en het niveau van een project 
hoger te tillen. Je bent onderzoeker in hart en nieren. 
Beste leden van de beoordelingscommissie, prof. dr. Tan, prof. dr. Nijsten, dr. Hoebers 
en prof. dr. Szeimies, Bedankt voor het lezen van dit manuscript en de tijd die u hierin 
gestoken hebt. Dear prof. Szeimies, thank you for your time to review this manuscript and 
participating in the evaluation committee of this thesis. 
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Ik waardeer uw komst naar mijn verdediging om te opponeren. Ook de overige corona 
leden wil ik hiervoor bedanken.
Beste dr. Nelemans, lieve Patty. Je had moeite met mijn huis te vinden tijdens onze eerste 
AKTI-meeting maar gelukkig wist ik de weg naar jouw kantoortje vaak genoeg te vinden! 
Ik ga onze gezellige gesprekken missen! Zonder (co)promotoren geen promotie, maar 
zonder Patty geen promotietraject! Jij hebt mij veel geleerd over statistiek (absence of 
evidence is not evidence of absence), maar vooral over wetenschap in het algemeen. Ik 
beloof je dat ik toch nog af en toe wat lekkers kom brengen ;) 
Beste dr. Essers, beste Brigitte. Ook aan jou dank voor je waardevolle en kritische blik 
op onze ZonMw subsidie-aanvraag en natuurlijk ook nu tijdens ons AKTI project. Jij kon 
als geen ander uitleggen hoe onderzoek naar kosten-effectiviteit en kwaliteit van leven 
in mekaar moet steken. Dank voor je rust en geduld. Er komt hopelijk nog een mooie 
publicatie aan waar we jouw hulp niet kunnen missen.   
Beste dr. Ir. Cleutjens, beste Jack. Dank voor jouw hulp bij de groene thee studie. De 
analyses waren Lotte en mij niet gelukt zonder jouw technische kennis en uitleg talent.
Beste dr. Winnepenninckx, beste Veronique. Beste dr. Hillen, beste Lisa. Dank de tijd en 
energie die jullie in de groene thee studie hebben gestoken. Dit was het enige pathologie 
project binnen mijn proefschrift, dus ik heb ontzettend veel van jullie dermato-pathologie 
kennis mogen leren. Bedankt voor jullie geduld en enthousiasme. 
Beste stafleden van het MUMC+. Ik kijk terug op een fantastische opleidingstijd, waarin 
ik veel heb kunnen leren en veel kansen heb gekregen. Ik wil jullie vooral ook bedanken 
voor alle vrijheid die jullie mij hebben gegeven om dit proefschrift te kunnen voltooien. 
Ook wil ik mijn eerste supervisoren bedanken uit de Eindhovense tijd. Marc, Gertruud, 
Judith en Simone, bij jullie is mijn interesse voor de dermatologie, maar ook voor weten-
schappelijk onderzoek begonnen. Bedankt voor jullie waardevolle hulp bij de eerste 
opstap van mijn carrière. 
Beste Maarten, hoe vaak ben ik niet in jouw kantoortje geweest om weer coupes op te 
halen voor de groene thee studie. Dank voor je zorgvuldigheid en altijd oprechte interesse 
in ons en onze projecten. 
Lieve Evelien en Mariska, de cover en de opmaak van dit boekje zijn te danken aan jullie 
creatieve input. Bedankt voor jullie ideeën, jullie durf en het uit handen nemen van heel 
veel werk! 
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Beste (inmiddels ex-) semi-artsen Nedim, Jolanda en Lotte. Bedankt voor jullie inzet en 
hulp bij een aantal projecten. Ik wens jullie allemaal een mooie carrière toe. 
En natuurlijk lieve Ellen, met jou is het schrijven van mijn eerste publicatie begonnen! Ik 
wens jou alle goeds en een glansrijke carrière toe. Gelukkig blijven we collega’s! 
Beste Germaine, Marie-Paule, Paulette en Marlène. Jullie hebben er zorg voor gedragen 
dat de PDT behandelingen tijdens de ALA vs MAL studie correct uitgevoerd werden in 
het MUMC+. 
Beste Anja, Joke, Elisabeth, Sandra en Claudia. Jullie zorgden er in het VieCuri, het Catharina 
en het Zuyderland ziekenhuis voor dat ook hier alles tot in de puntjes goed werd uitgevo-
erd voor deze studie. Later hebben jullie allemaal ook voor de AKTI-trial veel werk verzet. 
Beste Annie, jij zorgde er samen met Marie-Paule altijd voor dat alle patiënten van de ALA 
vs MAL-studie perfect ingepland werden in het MUMC+. Niets was te veel en chapeau 
voor jouw nauwkeurigheid. 
Zonder verpleegkundigen en ondersteunend personeel is de zorg voor patiënten niet 
mogelijk, maar ook voor het onderzoek hebben we jullie hard nodig!
Ik wil ook alle co-auteurs bedanken. Hilke en Ellen de Haas, jullie in het bijzonder bedankt 
voor de samenwerking tijdens de ALA vs MAL-studie. 
Kiki, ook jij bent een van de co-auteurs. Het is niet eerlijk, want de groene thee studie is 
jouw project. Ik ben nog steeds verdrietig dat je het niet hebt kunnen afmaken. Wat heb 
ik je kennis van de literatuur en nauwkeurigheid gemist. Je enthousiasme en vrolijkheid 
mis ik nog het meest. 
Beste secretariaat, Annelies, Nicole, Petra, Ingrid en Nandy. Zonder jullie administratieve 
ondersteuning was dit proefschrift ook een stuk lastiger geworden! In de ochtend bij bin-
nenkomst waren jullie er voor een praatje, gezelligheid en humor. Nicole jouw plan,- en 
organisatie talent is ongekend, dank voor al je hulp. Annelies jouw humor werkt aanste-
kelijk! Dank ook voor je hulp bij de laatste administratieve dingen rondom deze promotie. 
Beste oud-collega-AIOS. Bedankt voor de fijne tijd in het MUMC+. Ik heb soms heimwee 
naar de gezelligheid op het Oxford! Ik wens jullie allen het beste toe! 
Beste mede (oud-)promovendi: Tjinta, Marieke, Valerie, Maud, Marigje, Xiaomeng, Kelly en 
Eva. Bedankt dat we konden sparren en soms samen frustratie konden delen. Jullie mogen 
trots zijn op het werk dat jullie doen.   
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Lieve “studie-club” genootjes, Marloes, Femke, Charlotte, Manon en Xiaomeng. Toen ik 
pas naar Maastricht kwam vond het maar raar dat iedereen in een clubje zat om samen 
cursorisch onderwijs etc voor te bereiden. Nu kijk ik terug op veel gezellige avondjes, leuke 
cocoms en geweldige collega’s. Ik kijk uit naar nog vele reünies!  
Lieve collega’s in Heerlen. Wat ben ik nog iedere dag dankbaar dat ik bij jullie mag werken. 
Ik voel me als een vis in het water bij jullie; ik voel me thuis. Joost, Karen, Georges, Paul, 
Patricia en Manon, bedankt voor alle steun en vooral ook alles dat ik van jullie leer. Jullie 
zijn een voorbeeld.  
Mijn paranimfen, Maud en Manon. Wat ben ik blij en trots dat jullie aan mijn zijde staan 
tijdens deze bijzondere dag. Lieve Maud jij bent er eentje uit duizenden. Ik vind het onge-
lofelijk hoe enthousiast jij wordt van SPSS. We waren een goede match, jij prefereerde 
de statistiek, ik het schrijfwerk ;) Ik had me geen beter maatje kunnen bedenken voor de 
AKTI trial, dat weet je. Je hebt een ongekend doorzettingsvermogen en kritische blik en 
bent bovenal een lief en oprecht persoon. Jouw promotie komt helemaal goed! Ik kijk er 
nu al naar uit. 
Lieve Manon, dr. Ernst, collega! Wie had dat ooit gedacht. Jaren geleden begonnen we 
samen in Eindhoven en zie nu, werken we als directe collega’s samen. Wat hebben we 
allemaal meegemaakt. Zoals je in je eigen proefschrift schreef: “Ut kump wie ut kump, ut 
geet wie ut geet, ut hat nog ummer good gegange..”. Jij bent een grote motivator en ziet 
altijd de positieve dingen. Je bent een lief mens, gunt iedereen het beste en bent een 
geweldige mensen-dokter. Ik ben enorm blij met jou! 
Lieve vrienden en vriendinnen. Wat ben ik dankbaar met zoveel lieve mensen om mij 
heen. Door gebrek aan tijd en afstand zien we elkaar soms minder vaak dan we zouden 
willen. Lieve middelbare schoolvrienden, Sarah, Tom, Birte en Marius. Bedankt voor jullie 
vriendschap, ik kijk uit naar nóg meer gezelligheid. Monica, je kent me door en door en we 
kunnen in een deuk liggen om dingen die anderen niet snappen. Nog even en ook jouw 
proefschrift is klaar. Die koffie momenten op het werk houden we erin! Gonny en Patrick, 
een grote gebeurtenis staat te wachten: jullie eerste kindje. Gaat hij/zij daarna mee op de 
rug tijdens onze hike-avonturen? 
Lieve studie-vrienden, Rob, Roos, Eleana en Leo. Wat ben ik blij dat we bij elkaar in de 
eerste onderwijsgroep zaten! Marre, Constant, Krista en Nard: op naar nog vele “wine en 
dine” dates! 
Paul en Lidka, mr. & mrs van der Valk. Lied, ik hoop met jou nog een keer Afrika 2.0 te doen! 
Lieve vrienden uit Nijmegen: Sjoerd, Romy, Reinier, Sanne, Bas en Pien. Jullie betekenen 
veel voor mij en Martijn. Ik hoop dat we onze wintersport avonturen erin kunnen houden! 
Ik verheug me erop meer tijd met jullie allemaal te kunnen doorbrengen! 
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Lieve familie, bedankt voor jullie interesse en steun tijdens mijn opleiding en dit pro-
motietraject. Ik verheug me erop deze dag met jullie te delen en kijk uit naar de vele 
gezamenlijke momenten die nog komen gaan.
Beste schoonfamilie. Bedankt dat ik me bij jullie thuis voel. Ik hoop dat we nog veel mooie 
momenten samen mogen delen.  
Lieve Casper, schoonbroertje. Wat zijn we geschrokken afgelopen november. Ik ben 
ontzettend blij dat je er bent. Je vastberadenheid tot herstel vond ik ongekend. Ik neem 
een voorbeeld aan je doorzettingsvermogen. Je hebt een goed luisterend oor en kritische 
blik, dat maakt je een echte academicus. Ik bent trots op je.
Lieve oma Ritterbecks. Ook door jou ben ik wie ik ben. Wat een geweldige jeugd heb ik 
gehad in Lemiers. Ik ben ontzettend dankbaar dat je dit nog mee mag maken.
Lieve papa en mama, wat mag ik gelukkig zijn met ouders die mij altijd hebben gesteund 
met zo veel onvoorwaardelijke liefde. Zonder jullie was ik niet zo ver gekomen, jullie zijn 
mijn steun en toeverlaat. Papa, van jou heb ik geleerd dat de kleine dingen in het leven 
je geluk bepalen en hoe belangrijk het is ‘gewoon’ te blijven en te zijn wie je bent. Mama, 
jij bent degene bij wie ik zelfs midden in de nacht terecht kan als ik ergens mee zit. Jij 
voelt me als géén ander aan! Je bent een groot voorbeeld voor me. Dank jullie dat jullie 
er altijd voor mij zijn. De afgelopen maanden waren intensief, zeker nu we samen aan de 
verbouwing van jullie nieuwe woning zijn begonnen. Ik kijk ontzettend uit naar de toekomst 
samen op 1 erf ;) 
Allerliefste Martijn. Last but not least! Ik kan niet in woorden omschrijven hoe veel je voor 
me betekent. De lange wandeltochten samen waren de beste afleiding. Je vult me aan en 
geeft me rust. Je wist me de afgelopen jaren altijd te motiveren als ik het even niet zag 
zitten; je relativeringsvermogen en je uitleg over statistiek zijn onbetaalbaar. Je bent een 
echte wetenschapper, je zult schitteren tijdens jouw verdediging! Ik ben je dankbaar voor 
alle liefde die je geeft en heb respect voor hoe je mijn enthousiaste woordenvloed vaak 
aanhoort ;) Ik kijk ontzettend uit naar onze bruiloft in augustus. Ik ben trots op jou, op ons 
en ik zeg ja tegen onze toekomst! 
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Cover 
Op de cover ziet u een ruwe diamant. Aan de bovenzijde is een brede lichtbundel te zien 
en aan de onderzijde een smallere schaduw. De achterliggende gedachte bij deze cover is 
dat de ruwe – grove – diamant de aandoeningen weerspiegelt die dit proefschrift behan-
delt: actinische keratose en het superficieel basaalcelcarcinoom. Actinische keratose is een 
huidaandoening die zich presenteert als plekken met ruw aanvoelende schilfers. Bij het 
basaalcelcarcinoom worden vaak vertakkende bloedvaatjes gezien, welke in de diamant 
terug te zien zijn als ‘cracks’. Voor de oplettende kijker kan er ook een groen blad gezien 
worden, refererend aan de studie die wij verricht hebben naar groene thee zalf bij het 
basaalcelcarcinoom.  
Zowel het basaalcelcarcinoom als actinische keratose ontstaan door zonschade. 
In dit proefschrift worden meerdere niet-invasieve behandelingen besproken voor 
beide aandoeningen. Eén van die behandelingen betreft photodynamische ther-
apie (PDT), ook wel licht therapie genoemd. De lichtbundel aan de bovenzijde van de 
diamant weerspiegelt enerzijds het zonlicht en anderzijds de lichtbundel van PDT. 
In de conclusie van dit proefschrift wordt benadrukt dat er op de eerste plaats naar 
de meest (kosten)effectieve behandeling voor deze huidaandoeningen gekeken moet 
worden, maar dat niet iedere behandeling geschikt is voor de individuele patiënt. Dit wordt 
op de cover weergegeven als een smalle schaduw aan de onderzijde van de diamant. De 
gebroken stukjes diamant op de achterzijde van de cover weerspiegelen de diversiteit aan 
patiënten en behandelindicaties. 
